radium has been researched along with Bone Neoplasms in 483 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 113 (23.40) | 18.7374 |
1990's | 25 (5.18) | 18.2507 |
2000's | 23 (4.76) | 29.6817 |
2010's | 240 (49.69) | 24.3611 |
2020's | 82 (16.98) | 2.80 |
Authors | Studies |
---|---|
Agarwal, N; Bruno, A; George, D; Guo, H; Higano, CS; Jiao, X; Miller, K; Saad, F; Sandström, P; Sartor, O; Shore, N; Sternberg, CN; Tombal, B; Verholen, F | 1 |
Horio, T; Hosono, M; Kakehi, Y; Kinuya, S; Masumori, N; Okayama, Y; Sunaya, T; Takahashi, S; Uemura, H | 2 |
Akakura, K; Ledesma, DA; Miyazaki, K; Seo, C; Stroupe, A; Uemura, H; Uzumcu, A | 1 |
Alencar, LMR; Gemini-Piperni, S; Lima, RC; Santos-Oliveira, R; Yang, Y | 1 |
Anderson, P; Kairemo, K; Macapinlac, HA; Rao, A; Ravizzini, G; Roszik, J; Subbiah, V | 1 |
Abend, M; Barsegian, V; Eberlein, U; Hoffmann, MA; Lassmann, M; Majewski, M; Miederer, M; Nestler, T; Ostheim, P; Port, M; Rump, A; Schreckenberger, M | 1 |
Saganich, C; Zgaljardic, M | 1 |
Iwamoto, H; Izumi, K; Kadomoto, S; Kadono, Y; Kano, H; Makino, T; Mizokami, A; Naito, R; Shimada, T; Yaegashi, H | 1 |
Huang, LH; Ou, YC; Tseng, NC; Weng, WC | 1 |
Agarwal, N; Constantinovici, N; George, DJ; Guo, H; Higano, CS; Jiao, X; Miller, K; Reeves, J; Saad, F; Sandström, P; Sartor, O; Shore, N; Sternberg, CN; Tombal, B; Verholen, F | 1 |
Alencar, LMR; Batista, BDS; França, ARS; Gemini-Piperni, S; Lima, RC; Pijeira, MSO; Rates, ERD; Santos-Oliveira, R; Yang, Y | 1 |
Bambury, RM; Jamaluddin, MF; Kelly, P; Lyons, C; McCarthy, L; Peters, N; Power, DG | 1 |
El Khouli, R; Kunos, CA; Lemieux, B; Liu, X; Myint, ZW; St Clair, WH; Yan, D | 1 |
Bloom, JR; Castillejos, AG; Jones, B; Patel, N; Rosenstein, BS; Stock, RG | 1 |
Bryce, AH; Choo, R; Ho, TH; Jaeger, E; Kendi, AT; Keole, SR; Kosiorek, HE; Ledet, E; Liu, AJ; Moore, CN; Quevedo, F; Sartor, O; Singh, P; Tzou, K; Ueberroth, BE; Wong, WW | 1 |
Custers, JAE; Gerritsen, WR; Janssen, MJR; Mehra, N; Oving, IM; Oyen, WJG; Prins, JB; Terheggen, F; van Basten, JP; van de Luijtgaarden, ACM; van den Berkmortel, F; van der Doelen, MJ; van Oort, IM; van Schelven, WD; Wyndaele, DNJ | 1 |
Hasumi, H; Kawahara, T; Makiyama, K; Miyoshi, Y; Ninomiya, S; Sato, M; Takeshima, T; Uemura, H | 1 |
Alonso-Gordoa, T; Bonfill, T; Borrega, P; Carles, J; Collado, R; Gallardo, E; Garcías de España, C; Garde, J; González-Del-Alba, A; Malfettone, A; Mellado, B; Méndez-Vidal, MJ; Morales-Barrera, R; Paredes, P; Piulats, JM; Reig, O; Sampayo-Cordero, M; Suárez, C; Vázquez, S | 1 |
Braz, D; da Silva, AX; de Sá, LV; Lima, LFC; Segars, WP; Silva, CCO | 1 |
Doehn, C; Eichenauer, R; Grund, C; Hellmis, E; Hempel, E; Johannsen, M; Jores, C; Klier, J; König, F; Schönfelder, R; Schröder, J; Zillmann, R | 1 |
Eriksson, MH; Garcia-Albeniz, X; Kjellman, A; Lissbrant, IF; Martinez, D; Sandstrom, P; Stattin, P; Ullén, A; Vassilev, Z; Weinrib, R; Westerberg, M | 1 |
Kamoto, T; Kimura, T; Mukai, S; Nagano, M; Okabe, KO; Onizuka, C; Otuka, I; Shirakawa, T; Takamori, H; Terada, N; Ueno, T; Yamashita, Y | 1 |
Blas, L; Eto, M; Hori, Y; Kiyoshima, K; Kuroiwa, K; Matsumoto, T; Morokuma, F; Nakamura, M; Seki, N; Shiota, M; Yokomizo, A | 2 |
Daimon, T; Hosono, M; Igeta, M; Ishiwata, Y; Ito, K; Kawahara, T; Kitajima, K; Kono, Y; Kuyama, J; Miyake, H; Narita, M; Otani, T; Seko-Nitta, A; Suga, T; Sugawara, S; Tamaki, Y; Toriihara, A; Watanabe, S; Yamakado, K; Yamamoto, S | 1 |
Danilenko, VV; Shypko, AF; Solodyannikova, OI; Sukach, GG | 1 |
Attwood, K; George, S; Kothari, S; Lamonica, D; Levine, E; Shariftabrizi, A | 1 |
K Das, M; Mandal, S; Nayak, P; Ram, P | 1 |
Alencar, LMR; da Silva Batista, B; Gemini-Piperni, S; İlem-Özdemir, D; Ricci-Junior, E; Rossi, AM; Santos-Oliveira, R | 1 |
Alhoniemi, E; Haendler, B; Käkönen, SM; Knuuttila, M; Mumberg, D; Schatz, CA; Schlicker, A; Scholz, A; Sjöholm, B; Suominen, MI; Vääräniemi, J | 1 |
Briones, J; Emmenegger, U; Hardisty, MR; Khan, M; Lyons, F; Naimi, MF; Parshad, S; Phillips, CM; Sidhu, AK; Smoragiewicz, M; Whyne, CM | 1 |
Abramowitz, E; O'Sullivan, JM; Sierra-Scacalossi, L | 1 |
Chang, LW; Chen, CC; Chen, CS; Cheng, CL; Chiu, KY; Hung, SC; Li, JR; Lin, CY; Lu, K; Ou, YC; Wang, SC; Wang, SS; Yang, CK; Yang, HC | 1 |
Yuasa, T | 1 |
Alonzi, R; Blackledge, MD; Chatfield, P; Chua, S; Cook, GJR; Curcean, A; Du, Y; Finch, J; Hafeez, S; Hall, E; Koh, DM; Murray, I; Padhani, AR; Parker, C; Perry, S; Staffurth, J; Stidwill, H; Tovey, H; Tree, A; Tunariu, N | 1 |
Sartor, O | 3 |
Käkönen, SM; Scholz, A; Suominen, MI; Wilson, T | 1 |
Frank, SJ; Heinrich, D; Keizman, D; Li, R; Mariados, N; Méndez Vidal, MJ; Nordquist, LT; Peer, A; Procopio, G; Pulkkanen, K; Rosenbaum, E; Sartor, O; Severi, S; Thellenberg Karlsson, C; Trandafir, L; Trigo, J; Wagner, V | 1 |
Dizdarevic, S; McCready, R; Vinjamuri, S | 1 |
Fujii, Y; Hinotsu, S; Izumi, K; Kimura, G; Mizokami, A | 1 |
Leung, E | 1 |
Fricke, E; Goebell, PJ; Johannsen, M; Klier, J; König, F; Mehl, S; Mommsen, C; Pfister, D; Sahlmann, CO; Strauß, A; Werner, A | 1 |
Borsellino, N; Costa, R; Gebbia, V; Licari, M; Murabito, A; Princiotta, A; Sanfilippo, C; Scalici Gesolfo, C; Serretta, V; Tripoli, V; Valerio, MR; Verderame, F | 1 |
Corey, E; Guise, TA; Gulley, JL; Kevin Kelly, W; Morris, MJ; Quinn, DI; Scholz, A; Sgouros, G | 1 |
Hosono, M; Kakehi, Y; Kikukawa, H; Kimura, G; Kinuya, S; Krissel, H; Matsubara, N; Mizokami, A; Nagamori, S; Nakamura, M; Siegel, J; Uemura, H | 1 |
Chasen, BA; Damodaran, S; Fujii, T; Gao, H; Hortobagyi, GN; Ibrahim, NK; Iwase, T; Lim, B; Liu, DD; Lucci, A; Reuben, JM; Saigal, B; Shen, Y; Tahara, RK; Tripathy, D; Ueno, NT | 1 |
Aloise, I; Colosi, M; Farcomeni, A; Frantellizzi, V; Ippoliti, MD; Pani, A; Pani, R; Polito, C; Vincentis, G | 1 |
Badrising, SK; Beeker, A; Bergman, AM; Celik, F; Coenen, JLLM; Haanen, JB; Hamberg, P; Lam, MGEH; Loosveld, OJL; Louhanepessy, RD; Oostdijk, A; van der Noort, V; Vegt, E; Wagenaar, N; Zuetenhorst, H; Zwart, W | 1 |
Agarwal, N; Batten, J; Boucher, K; Gupta, S; Haaland, B; Hahn, AW; Hawks, J; Hoffman, JM; Maughan, BL; Morton, K; Nachaegari, G; Nussenzveig, R; Santos, VS; Thorley, J; Wang, X | 1 |
Anand, A; Brown, J; Brown, S; Coleman, R; Flanagan, L; Howell, S; Kendall, J; MacPherson, I; Palmieri, C; Rathbone, E; Reid, A; Twelves, C | 1 |
Davis, ID; Epstein, RJ; Graff, JN; Gurney, H; Hussain, M; Leung, E; Peer, A; Rosenbaum, E; Saad, F; Sternberg, CN; Trandafir, L; Vaishampayan, UN; Wagner, VJ; Wu, B | 1 |
Casadei, C; Cursano, MC; De Giorgi, U; Iuliani, M; Paganelli, G; Santini, D; Stellato, M; Tonini, G | 1 |
Albano, D; Bertagna, F; Cerudelli, E; Cossalter, E; Durmo, R; Gazzilli, M; Giubbini, R; Panarotto, MB | 1 |
Bagni, O; Basile, P; Filippi, L; Schillaci, O | 1 |
Brito, AE; Etchebehere, E | 1 |
Abou, DS; Finley, PA; Jha, AK; Riddle, RC; Rittenbach, A; Simons, BW; Thorek, DLJ; Tomlinson, RE; Tsui, B; Ulmert, D | 1 |
Chiti, A; Gelardi, F; Mazziotti, G; Pepe, G; Rodari, M; Tosi, G; Zucali, PA | 1 |
Agostini, S; Alongi, P; Baldari, S; Biasco, E; Borsatti, E; Bortolus, R; Caffo, O; Cortesi, E; De Vincentis, G; Facchini, G; Fanti, S; Filice, A; Frantellizzi, V; Galli, L; Masini, C; Monari, F; Pignata, S; Rossetti, S; Spada, M; Tucci, M; Zichi, C | 1 |
Dionisi, V; Fanti, S; Ghedini, P; Monari, F; Morganti, AG; Rizzini, EL | 1 |
Andreola, M; Cindolo, L; Cosma, L; Costa, R; De Vincentis, G; Dionisi, V; Farcomeni, A; Frantellizzi, V; Lavelli, V; Lodi Rizzini, E; Mascia, M; Monari, F; Murabito, A; Nappi, AG; Nuvoli, S; Rubini, G; Spanu, A | 1 |
Dorff, TB; Kortylewski, M; Posadas, E; Quinn, D; Stein, C; Synold, T | 1 |
Bruland, ØS; Juzeniene, A; Larsen, RH; Stenberg, VY | 1 |
George, DJ; Higano, CS; Jiao, X; Kalinovsky, J; Miller, K; Saad, F; Sartor, O; Shore, N; Sternberg, CN; Tangirala, K; Tombal, B | 1 |
Aben, KK; Bergman, AM; Celik, F; Coenen, JL; den Bosch, JV; der Meer, SV; Gerritsen, WR; Hendriks, MP; Kuppen, MC; Lavalaye, J; Polee, MB; Somford, DM; Uyl-de Groot, CA; van den Bergh, AC; van den Eertwegh, AJ; van der Doelen, MJ; van Oort, IM; Westgeest, HM | 1 |
Antonarakis, ES; Caldwell, T; Carducci, MA; Deek, MP; Denmeade, S; Deville, C; DeWeese, TL; Dipasquale, S; Dudley, S; Eisenberger, MA; Gorin, MA; Greco, SC; Hasan, H; Hobbs, RF; Huang, J; Kiess, AP; Leitzel, J; Malek, R; Markowski, M; Paller, CJ; Phillips, R; Pienta, KJ; Pomper, MG; Powell, J; Radwan, N; Rowe, SP; Song, DY; Thompson, E; Tran, PT; Wang, H; Wendler, D | 1 |
Banks, KP; Brown, RKJ; Buscombe, JR; Hurwitz, M; Jacene, HA; Klitzke, AK; Lamonica, D; Lu, Y; Pryma, DA; Rohren, EM; Speer, TW; Subramaniam, RM; Thompson, HM; Tomblyn, MB; Wong, WW; Xiao, Y | 1 |
Casarin, S; Dondossola, E | 1 |
Etchebehere, E; Lima, M; Minekawa, T; Moraes, A; Santos, A | 1 |
Hashimoto, K; Naito, M; Ukai, R | 1 |
Cindolo, L; Costa, RP; DE Vincentis, G; Dionisi, V; Farcomeni, A; Ferrari, C; Frantellizzi, V; Lavelli, V; Lodi Rizzini, E; Mascia, M; Monari, F; Nuvoli, S; Pontico, M; Rubini, G; Spanu, A; Tripoli, V | 1 |
Dandapani, SV; Twardowski, P; Wong, J | 1 |
Appukkuttan, S; Bhak, RH; Cheng, M; Duh, MS; Korves, C; McKay, RR; Silver, R; Simmons, SJ; Taplin, ME | 1 |
Kakimoto, KI; Kanaki, T; Nagahara, A; Nakai, Y; Nakayama, M; Nishimura, K; Okuda, Y; Tanaka, R; Yamamoto, Y | 1 |
Ahmadzadehfar, H; Conrad, R; Essler, M; Herrmann, K; Hirmas, N; Marinova, M; Sraieb, M | 1 |
Fukuta, F; Hashimoto, K; Hinotsu, S; Hori, M; Hotta, H; Kato, R; Kitamura, H; Kobayashi, K; Kunishima, Y; Maehana, T; Masumori, N; Miyamoto, S; Miyoshi, Y; Nishiyama, N; Okada, M; Sakata, KI; Shindo, T; Takahashi, A; Tanaka, T; Tsuboi, Y; Uemura, H; Yanase, M | 1 |
De Vincentis, G; Frantellizzi, V; Lazri, J; Pani, A; Pontico, M | 1 |
Chen, CH; Ding, Q; Guo, H; Guo, J; Jiang, Y; Krissel, H; Lee, JL; Li, F; Li, H; Li, R; Liu, X; Ma, J; Ng, QS; Park, SH; Shi, H; Sun, Y; Tian, Y; Wagner, VJ; Wang, S; Yao, X; Yuan, J; Zhang, X; Zheng, R; Zhou, D; Zhou, F; Zhou, T; Zou, Q | 1 |
De Vincentis, G; Frantellizzi, V | 1 |
Alongi, F; Alongi, P; Baldari, S; Biasco, E; Borsatti, E; Bortolus, R; Caffo, O; Cortesi, E; Costa, RP; Facchini, G; Fanti, S; Filice, A; Frantellizzi, V; Monari, F; Murabito, A; Palermo, A; Pignata, S; Pinto, C; Salgarello, M; Sbrana, A; Spada, M; Tucci, M; Vincentis, G; Zichi, C | 1 |
Gerritsen, WR; Ma, Y; Mehra, N; Nilsson, S; Stockhaus, A; Ullén, A; van der Doelen, MJ; van Oort, IM; Yachnin, J | 1 |
Amling, CL; Aronson, WJ; Cooperberg, MR; De Hoedt, AM; Freedland, SJ; Howard, LE; Kane, CJ; Klaassen, Z; Polascik, TJ; Terris, MK; Vidal, AC; Zhao, H | 1 |
Corn, P; Efstathiou, E; Gallick, GE; Gentile, E; Guerra, L; Hoang, A; Lee, YC; Lin, SC; Lin, SH; Logothetis, CJ; Madan, N; Melancon, MP; Navone, N; Panaretakis, T; Parikh, N; Santos, E; Song, JH; Subudhi, SK; Troncoso, P; Vardaki, I; Yu, G | 1 |
Abrantes, AM; Botelho, MF; Caramelo, FJ; Costa, G; Figueiredo, A; Gonçalves, AC; Marques, IA; Matafome, P; Neves, AR; Pereira, CC; Pires, AS; Rodrigues, T; Seiça, R; Tavares-da-Silva, E; Teixeira, JP | 1 |
Alongi, F; Alongi, P; Baldari, S; Borsatti, E; Bortolus, R; Caffo, O; Cortesi, E; Costa, RP; De Giorgi, U; De Vincentis, G; Donner, D; Facchini, G; Fanti, S; Frantellizzi, V; Galli, L; Lo Re, G; Masini, C; Monari, F; Morabito, A; Pignata, S; Pinto, C; Salgarello, M; Sbrana, A; Spada, M; Tucci, M; Zichi, C | 1 |
Alonzi, R; Blackledge, M; Chatfield, P; Curcean, S; Finch, J; Hall, E; Hijab, A; Mu Koh, D; Padhani, A; Parker, C; Perry, S; Staffurth, J; Stidwill, H; Tovey, H; Tree, A; Tunariu, N | 1 |
Appukkuttan, S; Sartor, O; Tsao, CK; Weiss, J | 1 |
Basch, EM; Brower, B; Crona, DJ; Dunn, MW; Godley, PA; Khandani, AH; Kim, SI; Milowsky, MI; Morgan, KP; Rose, TL; Szeto, AH; Whang, YE | 1 |
Falvello, V; Van Poznak, C | 1 |
Strane, T | 1 |
Amthauer, H; Genseke, P; Großer, OS; Kupitz, D; Ricke, J; Ruf, J; Wallbaum, T; Wissel, H | 1 |
Baldari, S; Boni, G; Bortolus, R; Caffo, O; Conti, G; De Vincentis, G; Monari, F; Procopio, G; Santini, D; Seregni, E; Valdagni, R | 1 |
Adamo, V; Baldari, S; Caffo, O; Franchina, T; Picciotto, M; Provazza, G; Ricciardi, GRR; Russo, A; Sava, S | 1 |
Doi, T; Hosono, M; Kinuya, S; Matsubara, N; Uemura, H; Yajima, Y | 1 |
Albert, NL; Bartenstein, P; Fendler, WP; Gratzke, C; Herlemann, A; Ilhan, H; la Fougère, C; Rominger, A; Stief, CG; Tirichter, N; Wenter, V | 1 |
García Cañamaque, L; García De la Peña, P; Rioja Parada, C | 1 |
Izumi, K; Kadono, Y; Kitagawa, Y; Konaka, H; Mizokami, A | 1 |
Saad, F; Traboulsi, SL | 1 |
Vogelzang, NJ | 2 |
Flux, GD | 1 |
Cozar-Olmos, JM; Figueiredo-de Castro, A; Juárez-Soto, A; Miñana-López, B; Rodríguez-Antolín, A; Silva-Marins, C; Sousa-Campo, R; Unda-Urzaiz, M | 1 |
Fukasawa, S; Hosono, M; Kawasaki, Y; Kikukawa, H; Kimura, G; Kinuya, S; Kosaka, T; Masumori, N; Matsubara, N; Mizokami, A; Nagamori, S; Nasu, Y; Sugiyama, T; Tsutsui, H; Uemura, H; Wakumoto, Y; Yamaguchi, I; Yokomizo, A; Yonese, J | 1 |
Aupee, O; Bertolaso, P; Cazeau, AL; Gross-Goupil, M; Le Moulec, S; Leroy, L; Ravaud, A; Roubaud, G | 1 |
Alvarez Cabellos, R; García Vicente, AM; Mohedano Mohedano, N; Sanchez Gil, B; Soriano Castrejón, Á | 1 |
Fosbøl, MØ; Kjaer, A; Mortensen, J; Petersen, PM | 1 |
Beuzeboc, P; Cachin, F; Deshayes, E; Hennequin, C; Houédé, N; Huglo, D; Kassab-Chahmi, D; Rebillard, X; Roumiguie, M; Rozet, F; Thibault, C | 1 |
George, DJ | 1 |
Frank, SJ; Heinrich, D; Keizman, D; Li, R; Mariados, N; Méndez Vidal, MJ; Nordquist, LT; Peer, A; Procopio, G; Pulkkanen, K; Rosenbaum, E; Sartor, O; Severi, S; Thellenberg Karlsson, C; Trigo Perez, JM; Wagner, V | 1 |
Grimm, MO; von Rundstedt, FC; Winter, BM | 1 |
Cha, TL; Chang, WY; Huang, CY; Huang, SP; Lin, CC; Ou, YC; Pang, ST; Shen, DH; Vogelzang, NJ; Wu, TT; Wu, WJ | 1 |
Carles, J; Climent, MÁ; Olmos, D; Pinto, Á; Rodriguez-Vida, A; Torregrosa, MD | 1 |
de Clermont, H; Laffon, E; Marthan, R; Paycha, F | 1 |
Kang, I; Kang, Y; Kim, JW; Petrylak, DP; Shin, MS | 1 |
Gerritsen, WR; Janssen, MJR; Jonker, MA; Kuppen, MCP; Mehra, N; van der Doelen, MJ; van Oort, IM | 1 |
Ichimura, A; Jinzaki, M; Nakahara, T; Nakajima, K; Owaki, Y | 1 |
Poon, DMC; Wong, KCW | 1 |
Chittenden, SJ; Flux, GD; Hindorf, C; Parker, CC; Pratt, BE | 1 |
Arranz, JA; Carles, J; Castellano, D; Del Alba, AG; Donas, JG; Esteban, E; Germà, JR; Hernando, S; Laínez, N; León, L; López-Brea, M; López-Criado, P; Maroto, P; Mellado, B; Méndez, MJ; Moretones, C; Pérez-Gracia, JL; Pérez-Valderrama, B; Pinto, Á; Reynés, G; Sáez, MI | 1 |
Andreeff, M; Becherer, A; Bockisch, A; Bodei, L; Delgado-Bolton, RC; Fricke, E; Gabriel, M; Geworski, L; Handkiewicz-Junak, D; Heinzel, A; Krause, BJ; Krause, T; Mitterhauser, M; Poeppel, TD; Sonnenschein, W | 1 |
Cicero, G; Costa, RP; De Luca, R; Murabito, A; Tripoli, V | 1 |
Fukai, S; Koizumi, M; Miyaji, N; Motegi, K; Nakazawa, S; Takiguchi, T; Umeda, T | 1 |
Barsanti, R; Zustovich, F | 1 |
De Vincentis, G; Farcomeni, A; Follacchio, GA; Frantellizzi, V; Pacilio, M; Pani, R; Pellegrini, R | 1 |
Mostaghel, EA; Pritchard, CC; Ramos, JD; Yu, EY | 1 |
Heidenreich, A; Nilsson, S; Parker, C; Shore, N | 1 |
Delgado Bolton, RC; Giammarile, F | 1 |
Coleman, RE; Den, R; Logothetis, C; Morris, MJ | 1 |
Amorim, BJ; Bernardo, WM; Brito, AE; Etchebehere, E; Martello, M | 1 |
Dainiak, N; Goans, RE; Iddins, CJ; McComish, SL; Tolmachev, SY; Toohey, RE | 1 |
Wei, ZF; Xu, XF; Zhang, ZY | 1 |
Gomella, L; Jacene, H; Rohren, EM; Yu, EY | 1 |
Fukada, J; Ichimura, A; Jinzaki, M; Kosaka, T; Nakahara, T; Owaki, Y | 1 |
Gillessen, S; Isensee, G; Müller, J; Omlin, A; Péporté, A; Schmid, S | 1 |
Mulders, PFA; Niepel, D; Saad, F; Sternberg, CN; Tombal, BF | 1 |
Bauriaud-Mallet, M; Ben Bouallègue, F; Brillouet, S; Caselles, O; Courbon, F; Dierickx, L; Gabiache, E; Kanoun, S; Pascal, P; Sinigaglia, M; Tal, I; Vallot, D; Vija Racaru, L; Zerdoud, S | 1 |
Abrantes, AM; Botelho, MF; Figueiredo, A; Marques, IA; Neves, AR; Pires, AS; Tavares-da-Silva, E | 1 |
Bruland, ØS; Herlofson, BB; Kjølle, GK; Løndalen, AM; Westgaard, KL | 1 |
Bottomley, D; Din, O; Dixit, S; Ferguson, C; Handforth, C; Henry, AM; Joseph, L; Kenning, L; Mokhtar, D; Murray, L; Parikh, S; White, L; Wright, G | 1 |
Canelón Castillo, E; Díez Farto, S; Jiménez Romero, ME; Navarro Serrato, JS; Revelo Cadena, I | 1 |
Etchebehere, E; Kairemo, K; Macapinlac, HA; Milton, DR; Rohren, EM | 1 |
Garla, VV; Kovvuru, KR; Salim, S; Subauste, A | 1 |
Álvarez-Ossorio, JL; Carballido-Rodríguez, J; Cozar-Olmo, JM; Gómez-Veiga, F; Juárez-Soto, A; Rodríguez-Antolín, A | 1 |
Arranz, JÁ; Carles, J; Castellano, D; González Del Alba, A; Jimenez, J; López, C; Manneh, R; Mellado, B; Méndez-Vidal, MJ; Morales-Barrera, R; Perez-Gracia, JL; Porras, I; Saez, MI; Sepúlveda, JM; Suárez, C | 1 |
Ferretti, A; Gross, MD; Rubello, D; Viglianti, BL; Wale, DJ; Wong, KK | 1 |
Afshar-Oromieh, A; Ahmadzadehfar, H; Essler, M; Rahbar, K | 1 |
Antonarakis, ES; Carducci, MA; Denmeade, SR; DeWeese, TL; Eisenberger, MA; Hassan, S; Isaacsson Velho, P; Markowski, MC; Qazi, F; Song, DY; Thorek, DL; Tran, PT | 1 |
Camargo Ibargarai, I; Lacasa-Viscasillas, I; Loizaga-Iriarte, A; Senarriaga-Ruiz de la Illa, N; Unda-Urzaiz, M | 1 |
Kratochwil, C; Levy, M; Lewington, V; Lindén, O; Noordzij, W; Park, J; Parker, C; Saad, F; Shore, N | 1 |
Iizuka, J | 1 |
Bryce, AH; Dorff, TB; Groshen, S; Ji, L; Quinn, DI; Wong, W; Yap, KK | 1 |
Danson, S; Geva, R; Harris, SJ; Joensuu, H; Lopez, J; Peer, A; Pereira, KMC; Perets, R; Souza, F | 1 |
Bloemendal, HJ; Bouman-Wammes, EW; de Klerk, JMH; Lange, R; Ter Heine, R; Van den Eertwegh, AJM; Van Dodewaard-de Jong, JM; Verheul, HMW | 1 |
Guerra Liberal, FDC; McMahon, SJ; Moreira, HMR; O'Sullivan, JM; Prise, KM | 1 |
Gerritsen, WR; Hermsen, R; Janssen, MJR; Mehra, N; van der Doelen, MJ; van Oort, IM | 1 |
Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M | 2 |
Casarin, S; De-Juan-Pardo, EM; Dondossola, E; Friedl, P; Hutmacher, DW; Logothetis, CJ; Paindelli, C | 1 |
Dondossola, E; Friedl, P; Logothetis, CJ; Navone, N; Paindelli, C | 1 |
Anderson, PM; Benjamin, RS; Chawla, S; Daw, NC; Hess, K; Hong, DS; Huh, WW; Kairemo, K; Kleinerman, E; Ludwig, JA; Macapinlac, H; Meric-Bernstam, F; Ravi, V; Ravizzini, G; Rohren, E; Somaiah, N; Subbiah, V | 1 |
Boegemann, M; Heidenreich, A; Higano, C; Kakehi, Y; Karyakin, O; Kimura, G; Krissel, H; Matsubara, N; Matveev, V; Miller, K; Nahas, WC; Ng, QS; Nolè, F; Parker, C; Piulats, JM; Rosenbaum, E; Saad, F; Shen, J; Smith, M; Teufel, M; Tombal, B; Wagner, V; Zhang, A; Zucca, LE | 1 |
Aranda-Lara, L; Azorín-Vega, E; Ferro-Flores, G; Jiménez-Mancilla, N; Nava-Cabrera, MA; Rojas-Calderón, E | 1 |
Den, RB; George, D; McNamara, M; Pieczonka, C | 1 |
Boni, G; Monari, F | 1 |
Akagawa, T; Fukasawa, S; Hosono, M; Kawasaki, Y; Kikukawa, H; Kimura, G; Kinuya, S; Kosaka, T; Masumori, N; Matsubara, N; Mizokami, A; Nagamori, S; Nasu, Y; Sugiyama, T; Uemura, H; Wakumoto, Y; Yamaguchi, I; Yokomizo, A; Yonese, J | 1 |
Carolino, E; Dizdarevic, S; Gape, P; Jessop, M; Pereira, L; Roque, V; Sousa, E | 1 |
Bellarosa, C; Cardano, R; Dionisi, V; Fanti, S; Ghedini, P; Monari, F; Morganti, AG; Rizzini, EL | 1 |
Anand, A; Anand, M; Armstrong, AJ; Chin, BB; George, DJ; McNamara, MA; Oldan, J; Oyekunle, T; Ritz, M; Shantzer, L | 1 |
Antonarakis, ES; Carrasquillo, JA; Deandreis, D; Fizazi, K; Higano, CS; Jacene, HA; Loriot, Y; Lu, C; Morris, MJ; Pandit-Taskar, N; Petrenciuc, O; Ryan, CJ; Shevrin, DH; Sweeney, CJ; Vesselle, H | 1 |
Iijima, M; Iwamoto, H; Izumi, K; Kadomoto, S; Kadono, Y; Kawaguchi, S; Makino, T; Matsuo, S; Mizokami, A; Nakashima, K; Nohara, T; Shigehara, K; Yaegashi, H | 1 |
Colasurdo, AP; Gallicchio, R; Guglielmi, G; Landriscina, M; Mainenti, PP; Mastrangelo, PA; Nardelli, A; Storto, G | 1 |
Anand, M; Armstrong, AJ; Davies, C; Foo, WC; George, DJ; Gerber, D; Giannakakou, P; Gregory, SG; Gupta, S; Halabi, S; Healy, P; Kemeny, G; Leith, B; Ribar, T; Rothwell, C; Somarelli, JA; Spritzer, C; Ware, K; Wood, K; Zalutsky, MR; Zhang, J | 1 |
Erdek, M; Sindhi, V | 1 |
Cortesi, E; De Vincentis, G; Farcomeni, A; Follacchio, GA; Frantellizzi, V; Pani, A; Samaritani, R; Santini, D; Schinzari, G | 1 |
Miranda, J; Pinto, Á; Viñal, D | 1 |
Morgan, SC | 1 |
Chittenden, SJ; Flux, GD; Gear, J; Murray, I; Parker, CC; Taprogge, J | 1 |
van der Poel, H | 1 |
Aro, JL; Dinning, SI; Leung, EY; Zuckier, LS | 1 |
Aksnes, AK; Carrasquillo, JA; Humm, JL; Lacuna, K; Larson, SM; Morris, MJ; O'Donoghue, JA; Pandit-Taskar, N; Rathkopf, DE; Scher, HI; Slovin, SF; Williamson, MJ | 1 |
Alhoniemi, E; Fagerlund, KM; Halleen, JM; Käkönen, R; Käkönen, SM; Mumberg, D; Rissanen, JP; Scholz, A; Suominen, MI; Ziegelbauer, K | 1 |
Kantoff, PW; Mohler, JL | 1 |
Boehmer, S; Bottomley, D; Bruland, ØS; Chodacki, A; Coleman, R; Dall'Oglio, M; Fosså, SD; Franzén, L; Garcia-Vargas, J; Heinrich, D; Helle, SI; Hoskin, P; James, ND; Johannessen, DC; Kliment, J; Logue, J; Nilsson, S; O'Bryan-Tear, CG; O'Sullivan, JM; Parker, C; Sartor, O; Seke, M; Shan, M; Solberg, A; Staudacher, K; Syndikus, I; Vogelzang, NJ; Wedel, S; Widmark, A; Wiechno, P | 1 |
Glatstein, E; Vapiwala, N | 2 |
Colletti, PM | 1 |
Ha, YS; Joung, JY; Kim, IY | 1 |
Gelderblom, H; van der Pluijm, G; van Leeuwen, FW; Wissing, MD | 1 |
Grivas, PD; Keller, ET | 1 |
Parker, C; Sartor, O | 2 |
Biersack, HJ; Ezziddin, S; Knapp, FF | 1 |
Ciezki, JP; Klein, EA; Tendulkar, RD; Ward, MC | 1 |
Asabella, AN; Nicoletti, A; Rubini, D; Rubini, G | 1 |
Al-Hakim, A; Alebachew, E; Chen, W; Haber, MT; Ibrahim, A; Justice, R; Kluetz, PG; Leutzinger, EE; Liu, Q; Maher, VE; Palmby, T; Pazdur, R; Pierce, W; Song, P; Sridhara, R; Tang, S; Zhang, H | 1 |
Armstrong, AJ; Bahnson, RR; Cohen, M; D'Amico, AV; Eastham, JA; Enke, CA; Farrington, TA; Higano, CS; Ho, M; Horwitz, EM; Kantoff, PW; Kawachi, MH; Kuettel, M; Lee, RJ; Macvicar, GR; Malcolm, AW; Miller, D; Mohler, JL; Plimack, ER; Pow-Sang, JM; Richey, S; Roach, M; Rohren, E; Rosenfeld, S; Shead, DA; Small, EJ; Srinivas, S; Stein, C; Strope, SA; Tward, J; Walsh, PC | 1 |
Carrasquillo, JA; Larson, SM; Pandit-Taskar, N | 1 |
Giammarile, F | 1 |
Taneja, SS | 2 |
Aksnes, AK; Awadallah, R; Biggin, C; Carrasquillo, J; Dauer, LT; Ghani, R; Humm, J; Morris, M; O'Donoghue, J; Pandit-Taskar, N; Reinton, V; St Germain, J; Williamson, MJ | 1 |
Higano, CS | 1 |
Heinzer, H; Klutmann, S; König, F | 1 |
McCormack, PL; Shirley, M | 1 |
Aksnes, AK; Coleman, R; Flamen, P; Garcia, C; Jerusalem, G; Naume, B; Piccart, M; Thuresson, M; Vobecky, N | 1 |
Den, RB; Doyle, LA; Knudsen, KE | 1 |
Bruland, ØS; Chodacki, A; Coleman, R; Fosså, SD; Heinrich, D; Helle, SI; Hoskin, P; James, ND; Johannessen, DC; Logue, J; Nilsson, S; O'Bryan-Tear, CG; O'Sullivan, JM; Parker, C; Sartor, O; Shan, M; Solberg, A; Syndikus, I; Vogelzang, NJ; Widmark, A; Wiechno, P | 1 |
Logothetis, CJ | 1 |
Roach, M | 1 |
Nilsson, S | 3 |
Anderson, PM; Rohren, E; Subbiah, V | 1 |
Boni, G; Borsò, E; Cianci, C; Falcone, A; Farnesi, A; Galli, L; Mariani, G; Mazzarri, S; Ricci, S | 1 |
Gartrell, BA; Saad, F | 1 |
O'Sullivan, J; Turner, PG | 1 |
Everly, JJ; Ryan, CJ; Sartor, O; Saylor, PJ | 1 |
Géczi, L; Sinkovics, I | 1 |
Højgaard, L; Mortensen, J | 1 |
Guerra Liberal, FD; Tavares, AA; Tavares, JM | 1 |
Den, RB; Kelly, WK | 1 |
Aksnes, AK; Bottomley, D; Fang, F; Helle, SI; Hoskin, P; Johannessen, DC; Logue, J; Nilsson, S; O'Sullivan, JM; Parker, C; Sartor, O; Vogelzang, NJ; Wahba, M | 1 |
Bjøro, T; Bogsrud, TV; Fosså, SD; Hernes, E; Nome, R | 1 |
Baba, S; Honda, H; Nakamura, K; Ohga, S; Sasaki, T | 1 |
Afonso Afonso, FJ; Anido Herranz, U; Antón Aparicio, LM; Fernández Calvo, O; Lázaro Quintela, M; León Mateos, L; Rodríguez Martínez de Llano, S; Vázquez Estévez, S | 1 |
Horton, ER; McGann, S | 1 |
Bilusic, M; Chen, D; Ito, T | 1 |
Shore, ND | 2 |
Slovin, SF; Yeku, O | 1 |
Challa, S; Conti, PS; Jadvar, H; Quinn, DI | 1 |
Hall, NC; Monk, JP; Murrey, DA; Wright, CL | 1 |
O'Sullivan, JM; Turner, PG | 1 |
Bergeron, DE; Cessna, JT; Fitzgerald, R; King, L; Pibida, L; Zimmerman, B | 1 |
Bruland, OS; Humm, JL; Macklis, R; Parker, C; Sartor, O | 1 |
George, DJ; McNamara, MA | 1 |
Dorff, TB; Gross, ME | 1 |
Araujo, JC; Etchebehere, EC; Fox, PS; Macapinlac, HA; Rohren, EM; Swanston, NM | 1 |
Beer, TM; Graff, JN | 1 |
Body, JJ; Casimiro, S; Costa, L | 1 |
Coleman, R; Efstathiou, E; Fizazi, K; Gartrell, BA; Logothetis, CJ; Saad, F; Sartor, O; Smith, MR; Sonpavde, G | 1 |
Chalhoub, E; Chalouhy, C; Lewis, B; Sartor, O | 1 |
Bilen, MA; Lin, SH; Tu, SM | 1 |
Chittenden, SJ; Flux, GD; Hindorf, C; Johnson, B; Lewington, VJ; Parker, CC; Pratt, BE | 1 |
Siegel, JA; Stabin, MG | 1 |
Bienz, M; Saad, F | 1 |
Cassano, B; De Vincentis, G; Di Castro, E; Follacchio, GA; Frantellizzi, V; Garkavaya, T; Ialongo, P; Lorenzon, L; Mango, L; Pacilio, M; Pani, R; Pellegrini, R; Ventroni, G | 1 |
Besenyi, Z; Pávics, L | 1 |
Armstrong, AJ; Li, J | 1 |
Makis, W; McCann, K; McEwan, AJ; Sawyer, MB | 1 |
Bloemendal, HJ; de Klerk, JM; Hoekstra, OS; Hooft, L; Jong, JM; Oprea-Lager, DE; van den Eertwegh, AJ; Verheul, HM | 1 |
Baqué, PE; Beck, J; Hampel, C; Helisch, A; Krieger, C; Miederer, M; Schreckenberger, M; Thomas, C | 1 |
Chowdhury, S; Gilson, C; Kirby, R; Manickavasagar, T | 1 |
Adams, S; Paryani, B; Subbiah, V; Takalkar, A | 1 |
Cassano, B; Di Castro, E; Ialongo, P; Lorenzon, L; Mango, L; Pacilio, M; Recine, F; Sternberg, CN; Ventroni, G | 1 |
Abou, DS; Doucet, M; Hobbs, RF; Riddle, RC; Thorek, DL; Ulmert, D | 1 |
Kirchner, V; Papazyan, JP | 1 |
Knight, H; McVeigh, G; Umeweni, N | 1 |
Araujo, JC; Erwin, WD; Etchebehere, EC; Fox, P; Macapinlac, HA; Milton, DR; Rohren, EM; Swanston, NM; Wendt, RE | 1 |
Coleman, R | 1 |
Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
Ahmadzadehfar, H; Essler, M; Gaertner, F; Schlenkhoff, CD; Schmidt, M | 1 |
Cislo, P; Coleman, RE; Nilsson, S; O'Sullivan, JM; Parker, C; Reuning-Scherer, J; Sartor, O; Shan, M; Vogelzang, NJ; Zhan, L | 1 |
Coleman, RE; Hoskin, P; Nilsson, S; Parker, C; Petrenciuc, O; Sartor, O; Staudacher, K; Thuresson, M; Vogelzang, NJ | 1 |
Dellavedova, L; Florimonte, L; Maffioli, LS | 1 |
Cortesi, E; De Vincentis, G; Follacchio, GA; Frantellizzi, V; Liberatore, M; Monteleone, F | 1 |
Hino, A; Inoue, T; Kaneko, M; Kaneta, T; Kawano, T; Shizukuishi, K; Sugiura, M; Takano, S; Yamamoto, T; Yoshida, K; Zurth, C | 1 |
Bottomley, D; Bruland, Ø; Coleman, RE; Finkelstein, SE; Li, R; Michalski, JM; Nilsson, S; O'Sullivan, JM; Parker, C; Sartor, O; Seger, MA; Vogelzang, NJ | 1 |
Dan, TD; Den, RB; Doyle, L; Gomella, LG; Pridjian, A; Raval, AJ | 1 |
Barkin, J | 1 |
Dermine, A; Machiels, JP | 1 |
Ahmadzadehfar, H; Essler, M; Rogenhofer, S; Schlenkhoff, CD; Yordanova, A | 1 |
Andreeff, M; Becherer, A; Bockisch, A; Fricke, E; Gabriel, M; Geworski, L; Heinzel, A; Krause, BJ; Krause, T; Mitterhauser, M; Pöppel, TD; Scheidhauer, K; Schenck, M; Sonnenschein, W | 1 |
Carles, J; Federhofer, J; Gillessen, S; Gratt, J; Heidenreich, A; Heinrich, D; Lévy, J; Miller, K; Nilsson, S; O'Sullivan, JM; Petrenciuc, O; Saad, F; Tucci, M; Wirth, M | 1 |
Dahut, WL; Gulley, JL; Madan, RA | 1 |
Parker, C; Wilson, JM | 1 |
Thoma, C | 1 |
Aarts, MJ; Badrising, SK; Bergman, AM; Coenen, JL; de Jong, IJ; Gelderblom, H; Haanen, JB; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Voorthuizen, T; Vrijaldenhoven, S | 1 |
Edwards, CM; Turner, CJ | 1 |
Coleman, RE; Germino, J; Michalski, JM; Nilsson, S; O'Sullivan, JM; Parker, C; Sartor, O; Thuresson, M; Vogelzang, NJ; Widmark, A; Xu, L | 1 |
Alho, I; Casimiro, S; Costa, L; Ferreira, AR; Mansinho, A | 1 |
Ahmadzadehfar, H; Azgomi, K; Essler, M; Gaertner, FC; Hauser, S; Kürpig, S; Strunk, H; Wei, X; Yordanova, A | 1 |
Cotogno, P; Ledet, EM; Lewis, B; Sartor, O; Steinberger, AE | 1 |
Aprile, C; Buroni, FE; Lodola, L; Nano, R; Pasi, F; Persico, MG | 1 |
Miyahira, AK; Morris, M; Soule, HR | 1 |
Baiocco, C; Genovese, S; Poti, C; Scalzi, P; Sirotova, Z; Trevisan, A | 1 |
Cislo, P; Coleman, RE; Nilsson, S; O'Sullivan, JM; Parker, C; Reuning-Scherer, J; Sartor, O; Vogelzang, NJ; Zhan, L | 1 |
Gunturu, K; Kewalramani, T; Tretter, C; Varkaris, A | 1 |
Eiber, M; Gschwend, J; Krönke, M; Scheidhauer, K; Tauber, R | 1 |
Ágoston, P; Bíró, K; Böde, I; Bodrogi, I; Dank, M; Géczi, L; Gyergyay, F; Kolonics, Z; Küronya, Z; Nagyiványi, K; Rúzsa, Á; Sinkovics, I; Vajdics, T | 1 |
Odo, U; Sartor, O; Vasudevamurthy, AK | 1 |
Airoldi, M; Angusti, T; Buttigliero, C; Manfredi, M; Parente, A; Tucci, M | 1 |
Alibhai, SMH; Emmenegger, U; Finelli, A; Hotte, SJ; Morgan, SC; Walker-Dilks, C; Winquist, E; Zukotynski, K | 1 |
Cathomas, R; Daugaard, G; Desax, MC; Dresler, H; Fosboel, MO; Gillessen, S; Gottfried, M; Keizman, D; Mermershtain, W; Mortensen, J; Mueller, J; Neiman, V; Omlin, A; Peer, A; Petersen, PM; Reichegger, H; Rosenbaum, E; Rouvinov, K; Sarid, D | 1 |
Liepe, K | 1 |
Kamoto, T | 1 |
Flux, GD; Hindorf, C; Ibisch, C; Kraeber Bodéré, F | 1 |
Agarwal, N; Sonpavde, G; Sternberg, CN | 1 |
Aksnes, AK; Andersson, C; Bruland, ØS; Franzèn, L; Nilsson, S; Olivier, P; Pecking, A; Staffurth, J; Strang, P; Vasanthan, S | 1 |
Lewis, B; Sartor, O | 1 |
Mackiewicz-Wysocka, M; Pankowska, M; Wysocki, PJ | 1 |
Aksnes, AK; Chittenden, S; Flux, GD; Hindorf, C; Parker, C | 1 |
Cheetham, PJ; Petrylak, DP | 1 |
Chang, AJ; Roach, M | 1 |
Silberstein, EB | 1 |
O'Sullivan, JM; Parker, CC; Vengalil, S | 1 |
Brugge, D; Buchner, V | 1 |
Badawi, JK | 1 |
Buscombe, J; Navalkissoor, S | 1 |
Chodacki, A; Germá, JR; Haider, T; Hoskin, P; O'Bryan-Tear, CG; O'Sullivan, JM; Parker, CC; Pascoe, S | 1 |
Blom, R; Bolstad, B; Bruland, ØS; Franzén, L; Johannessen, DC; Lennernäs, B; Nilsson, S; O'Bryan-Tear, CG; Parker, C; Petersson, U; Pigott, K; Sokal, M; Tennvall, J; Thuresson, M; Tyrrell, C | 1 |
Bellmunt, J | 1 |
Croke, J; Leung, E; Malone, S; Segal, R | 1 |
Armstrong, AJ; Fizazi, K; Freedland, S; Pienta, K; Saad, F; Saylor, PJ; Smith, MR; Tombal, B | 1 |
Hafeez, S; Parker, C | 1 |
Kerr, C | 1 |
Bijwaard, H; Brugmans, MJ; Leenhouts, HP | 2 |
Harrison, JD; Muirhead, CR | 1 |
Bowman, BM; Lloyd, RD; Miller, SC; Taylor, GN | 1 |
MARINELLI, LD | 1 |
POPPE, H; SCHOEN, H; SPIESS, H | 1 |
WOODARD HQ HIGINBOTHAM, NL | 1 |
SPIERS, FW | 3 |
DAHLIN, DC; HOLTZMAN, RB; LUCAS, HF | 2 |
JANOWER, ML | 1 |
NAHUM, AM | 1 |
BEAL, DD; LINDSAY, JR; WARD, PH | 1 |
FINKEL, AJ; HASTERLIK, RJ; MILLER, CE | 2 |
BRIGHTON, CT; BUNDENS, WD | 1 |
Gössner, W | 6 |
HOECKER, FE; ROOFE, PG | 1 |
AUERBACH, H | 1 |
Heidenreich, WF; Müller, WA; Paretzke, HG; Rosemann, M | 1 |
Balteskard, L; Borch, KW; Bruland, OS; Fosså, SD; Larsen, RH; Nilsson, S; Salberg, G; Westlin, JE | 1 |
Bruenger, FW; Jee, WS; Lloyd, RD; Miller, SC; Taylor, GN | 3 |
Altavilla, G; Aricò, D; Baldari, S; Herberg, A; Minutoli, F; Restifo Pecorella, G; Spadaro, P | 1 |
Bruland, ØS; Fisher, DR; Larsen, RH; Nilsson, S | 1 |
Bijwaard, H | 1 |
Berdon, WE; Liebling, MS; Marcovici, PA | 1 |
Blom, R; Bolstad, B; Bruland, OS; Franzén, L; Garkavij, M; Harmenberg, J; Johannessen, DC; Lennernäs, B; Nilsson, S; Parker, C; Petersson, U; Pigott, K; Sokal, M; Strang, P; Tennvall, J; Tyrrell, C; Yachnin, J | 1 |
Mason, MD; Shelley, MD | 1 |
Amaral, A; Amaral, RS; Silva, CM | 1 |
Hems, G | 2 |
Raabe, OG | 2 |
Gössner, W; Luz, A; Müller, WA; Schäffer, EH | 1 |
Beddoe, AH; Spiers, FW | 1 |
Filiushkin, IV; Petoian, IM | 1 |
Luz, A; Schoeters, GE; Vanderborght, OL | 1 |
Atherton, DR; Ayoroa, G; Brammer, D; Brammer, TW; Gardner, PA; Lloyd, RD; Mays, CW; McFarland, SS; Pollard, TA; Talbot, LR; Taylor, GN; Taysum, DH; VanMoorhem, D | 1 |
Bruenger, FW; Jones, CW; Lloyd, RD; Mays, CW; Taylor, GN | 1 |
Sharpe, WD | 3 |
Henning, CB; Lloyd, EL | 1 |
Lucas, HF; Rowland, RE; Stehney, AF | 2 |
Gössner, W; Wick, RR | 1 |
Book, SA; Parks, NJ; Raabe, OG | 3 |
Kirsh, IE; Morgan, JP; Pool, RR | 1 |
Angus, W; Atherton, DR; Mays, CW; Shabestari, L; Taylor, GN; Thurman, GB | 1 |
Book, SA; Chrisp, CE; Goldman, M; Parks, NJ; Raabe, OG | 1 |
Finkelstein, MM | 1 |
Angus, W; Bruenger, FW; Jee, WS; Lloyd, RD; Miller, SC; Taylor, GN | 1 |
Culbertson, MR; Parks, NJ; Raabe, OG; Rosenblatt, LS; Samuels, SJ; White, RG | 1 |
Lloyd, RD | 1 |
Finkelstein, MM; Kreiger, N | 1 |
Boecker, BB; Griffith, WC; Hahn, FF; Lloyd, RD; Muggenburg, BA | 1 |
Carnes, BA; Groer, PG; Kotek, TJ | 1 |
Jee, WS; Li, XJ; Lloyd, RD; Mays, CW; Miller, SC; Mori, S; Shabestari, L; Taylor, GN | 1 |
Lloyd, RD; Miller, SC; Taylor, GN; Thurman, GB | 1 |
Fry, SA | 1 |
Jee, WS; Lloyd, RD; Miller, SC; Taylor, GN | 1 |
Fisher, DR; Lloyd, RD; Miller, SC; Schlenker, RA | 1 |
Eder, E; Kellerer, AM; Kuse-Isingschulte, M; Nekolla, EA; Spiess, H | 1 |
Gössner, W; Kellerer, AM; Nekolla, EA; Wick, RR | 1 |
Gössner, W; Kellerer, AM; Kreisheimer, M; Kuse-Isingschulte, M; Nekolla, EA; Spiess, H | 1 |
Brugmans, MJ; Leenhouts, HP | 1 |
Lloyd, RD; Miller, SC; Taylor, GN | 1 |
Fisher, DR; Lloyd, RD; Miller, SC; Schlenker, RA; Taylor, GN | 1 |
Chadwick, KH | 1 |
Breistøl, K; Bruland, ØS; Fodstad, Ø; Henriksen, G; Larsen, RH | 1 |
Gössner, W; Hug, O; Luz, A; Müller, WA | 3 |
Thorne, MC | 1 |
Luz, A; Müller, WA | 1 |
Bubeniková, D; Dvorák, V; Kofránek, V; Kotasková, Z; Svoboda, V | 1 |
Bubeníková, D; Kofránek, V; Machek, J; Parízek, O; Svoboda, V | 1 |
Beddoe, AH; King, SD; Spiers, FW | 1 |
Mays, CW | 3 |
Mole, RH | 1 |
Momeni, MH | 1 |
Brady, LW | 1 |
Mays, CW; Spiess, H | 4 |
Polednak, AP | 1 |
Brues, AM; Keane, AT; Littman, MS; Patten, BC; Rowland, RE; Shanahan, MM; Stehney, AF | 1 |
Spiers, FW; Vaughan, J | 1 |
Groer, PG; Marshall, JH | 1 |
Ardran, GM; Corp, MJ; Loutit, JF | 1 |
Lloyd, EL; Loutit, JF; Mackevicius, F | 1 |
Atkinson, MJ; Erfle, V; Gössner, W; Linzner, U; Luz, A; Müller, K; Müller, WA; Murray, AB; Schmidt, J; Strauss, PG | 1 |
Raabe, OG; Rosenblatt, LS; Schlenker, RA | 1 |
Chmelevsky, D; Kellerer, AM; Spiess, H | 1 |
Angus, W; Bruenger, FW; Jee, WS; Lloyd, RD; Miller, SC; Polig, E; Taylor, GN | 1 |
Bruenger, FW; Lloyd, RD; Miller, SC | 1 |
Maisin, JR; Schoeters, GE; Vanderborght, OL | 1 |
Chmelevsky, D; Kellerer, AM; Mays, CW; Spiess, H | 2 |
Linzner, U; Luz, A; Müller, WA; Murray, AB | 1 |
Erfle, V; Luz, A; Schmidt, J | 1 |
Priest, ND | 1 |
Lloyd, RD; Mays, CW; Taylor, GN; Wrenn, ME | 1 |
Bubeníková, D; Dvorák, V; Kofránek, V; Sedlák, A | 1 |
Mays, CW; Rowland, RE; Stehney, AF | 1 |
Durbin, PW; Howard, B; Lipsztein, J; Rundo, J; Still, ET; Willis, DL; Wrenn, ME | 1 |
Jones, CW; Lloyd, RD; Mays, CW; McFarland, SS; Packer, SM; Smith, JM; Taylor, GN | 1 |
Keane, AT; Lucas, HF; Rundo, J; Schlenker, RA; Stebbings, JH; Stehney, AF | 1 |
Chmelevsky, D; Kellerer, A; Mays, CW; Spiess, H | 1 |
Chmelevsky, D; Gössner, W; Wick, RR | 1 |
Dell, RB; Jee, WS; Miller, SC; Parks, NJ | 1 |
Luz, A; Müller, WA; Schäffer, EH | 1 |
Becker, G; Lepp, C; Luz, A; Pömsl, H | 1 |
Kondrat'eva, AF | 1 |
Hutchison, GB | 1 |
Gössner, W; Hindringer, B; Hug, O; Luz, A; Müller, WA | 1 |
Eschwège, F; Le Bourgeois, JP; Schlienger, M | 1 |
Blair, HA | 2 |
Pesternikov, VM | 1 |
Marquart, KH | 1 |
Holusa, R; Kofrånek, V; Onyskowovå, Z | 1 |
Rowland, RE; Rundo, J | 1 |
Piller, S | 1 |
Gössner, W; Hindringer, B; Luz, A | 1 |
Dalinka, MK; Edeiken, J; Finkelstein, JB | 1 |
Abrahams, SP; Lucas, HF; Petersen, NJ; Samuels, LD | 1 |
Murphy, WT | 1 |
Evans, RD | 1 |
Loutit, JF | 1 |
Dougherty, TF; Jee, WS; Mays, CW; Taylor, GN | 1 |
Gofman, JW; Tamplin, AR | 1 |
Gridgeman, NT | 1 |
Arlen, M; Higinbotham, NL; Huvos, AG; Marcove, RC; Miller, T; Shah, IC | 1 |
Globocnik, E; Kofránek, V; Svoboda, V | 1 |
Müller, WA | 1 |
Bernier, L; Delage, C | 1 |
Bulgin, MS; Goldman, M; Williams, RJ | 1 |
Goss, SG | 1 |
Kratochwil, A; Tatra, G | 1 |
Evans, RD; Finkel, AJ; Hasterlik, RJ; Keane, AT; Kolenkow, RJ; Neal, WR; Shanahan, MM | 1 |
Boyd, JT; Doll, R; Hill, GB; Sissons, HA | 1 |
Hems, G; Mole, RH | 1 |
CHARKES, ND; SKLAROFF, DM | 1 |
111 review(s) available for radium and Bone Neoplasms
Article | Year |
---|---|
RADIONUCLIDE THERAPY FOR BONE LESIONS IN CASTRATION-RESISTANT PROSTATE CANCER (STATE-OF-THE-ART LITERATURE REVIEW).
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium | 2022 |
Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary.
Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Humans; Molecular Targeted Therapy; Osteoblasts; Osteoclasts; Prognosis; Radioisotopes; Radium | 2019 |
Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.
Topics: Actinium; Astatine; Bismuth; Bone Neoplasms; Humans; Lead Radioisotopes; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Thorium | 2020 |
[Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) : The androgen receptor-independent active agent in the therapeutic sequence].
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radiopharmaceuticals; Radium; Receptors, Androgen | 2020 |
Radium-223 mechanism of action: implications for use in treatment combinations.
Topics: Animals; Bone Neoplasms; Combined Modality Therapy; Disease Models, Animal; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
Topics: Androstenes; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; Tumor Microenvironment | 2020 |
Radium-223 as an Approved Modality for Treatment of Bone Metastases.
Topics: Bone Neoplasms; Drug Approval; Humans; Isotope Labeling; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2020 |
Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Neoplasms; Chemoradiotherapy; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome; Tumor Microenvironment | 2020 |
Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer.
Topics: Alpha Particles; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Chemoradiotherapy; Humans; Male; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Updates in Management of Bone Metastatic Disease in Primary Solid Tumors with Systemic Therapies.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Humans; Radiopharmaceuticals; Radium; Zoledronic Acid | 2021 |
Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
Topics: Bone Neoplasms; Disease Management; Docetaxel; Humans; Italy; Male; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Treatment Outcome | 2017 |
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Disease-Free Survival; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic | 2017 |
Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
The role of bone-targeted therapies for prostate cancer in 2017.
Topics: Androstenes; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Survival Rate; Treatment Outcome | 2017 |
Imaging and dosimetry for radium-223: the potential for personalized treatment.
Topics: Bone Neoplasms; Humans; Male; Precision Medicine; Prostatic Neoplasms; Radioisotopes; Radiometry; Radium | 2017 |
Radium-223 in the therapeutic sequence of metastatic castration-resistant prostate cancer.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2018 |
[Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts].
Topics: Alpha Particles; Beta Particles; Bone Neoplasms; Cancer Pain; Clinical Trials as Topic; Gamma Rays; Humans; Male; Prostatic Neoplasms; Radiation Protection; Radiopharmaceuticals; Radium | 2017 |
Radium 223 dichloride for prostate cancer treatment.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; DNA Breaks, Double-Stranded; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Tumor Microenvironment | 2017 |
[Radium-223 dichloride in patients with castration-refractory prostate cancer].
Topics: Androstenes; Benzamides; Bone Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Denosumab; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment | 2017 |
Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
Topics: Bone Neoplasms; Clinical Trials as Topic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Treatment Outcome | 2017 |
Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.
Topics: Bone Neoplasms; Humans; Male; Patient Selection; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium | 2018 |
Targeted α Therapies for the Treatment of Bone Metastases.
Topics: Alpha Particles; Bone Neoplasms; Brachytherapy; Dose-Response Relationship, Radiation; Humans; Male; Practice Guidelines as Topic; Prostatic Neoplasms; Radioisotopes; Radium; Randomized Controlled Trials as Topic | 2017 |
Current approaches to incorporation of radium-223 in clinical practice.
Topics: Androstenes; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Receptors, Androgen; Taxoids; Treatment Outcome | 2018 |
Current perspectives on bone metastases in castrate-resistant prostate cancer.
Topics: Animals; Biomarkers, Tumor; Bone Neoplasms; Disease Models, Animal; Disease Progression; Humans; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Prostate cancer - Therapy with radium-223.
Topics: Antineoplastic Agents; Bone Neoplasms; Brazil; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Humans; Male; Placebos; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiotherapy Dosage; Radium; Randomized Controlled Trials as Topic; Risk Factors; Societies, Scientific; Survival Rate | 2017 |
[Radium-223 for the treatment of bone metastasis of prostate cancer].
Topics: Bone Neoplasms; Clinical Trials as Topic; Humans; Male; Prostatic Neoplasms; Quality of Life; Radioisotopes; Radium | 2017 |
Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations.
Topics: Bone Neoplasms; Clinical Trials, Phase III as Topic; Hematologic Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Treatment Outcome | 2018 |
The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.
Topics: Abiraterone Acetate; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Taxoids; Zoledronic Acid | 2018 |
Targeted alpha therapy using Radium-223: From physics to biological effects.
Topics: Alpha Particles; Animals; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2018 |
Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity.
Topics: Abdominal Neoplasms; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Time Factors; Viscera | 2018 |
Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
Topics: Bone Neoplasms; Clinical Trials as Topic; Humans; Lutetium; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Radium | 2019 |
Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning.
Topics: Bone Neoplasms; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Pain; Patient Care Planning; Positron-Emission Tomography; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Radium | 2018 |
Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.
Topics: Alpha Particles; Bone Neoplasms; Humans; Male; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiotherapy; Radium; Therapies, Investigational | 2018 |
Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.
Topics: Bone Neoplasms; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radium; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone.
Topics: Bone Neoplasms; Cancer Pain; Clinical Trials as Topic; Combined Modality Therapy; Drug Therapy; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Survival Analysis; Treatment Outcome | 2019 |
Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives.
Topics: Bone Neoplasms; Clinical Trials as Topic; Humans; Male; Patient Selection; Practice Guidelines as Topic; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2019 |
Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.
Topics: Bone Neoplasms; Disease Management; Humans; Male; Patient Selection; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Radium; Samarium; Strontium Radioisotopes | 2019 |
Interventional treatments for metastatic bone cancer pain.
Topics: Analgesics, Opioid; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Humans; Pain Management; Radium | 2019 |
Radium 223 for the treatment of metastatic castration-resistant prostate cancer.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium | 2019 |
Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radiobiology; Radiopharmaceuticals; Radium | 2019 |
Safe Use of Radium-223 Dichloride (
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Radiation Exposure; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Radium; Safety Management; Tissue Distribution | 2019 |
New developments in the management of prostate cancer.
Topics: Androgens; Antineoplastic Agents; Bone Neoplasms; Humans; Immunotherapy; Male; Prostatic Neoplasms; Radioisotopes; Radium; Salvage Therapy; Signal Transduction | 2013 |
Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Evaluation, Preclinical; Humans; Male; Prostatic Neoplasms; Radioisotopes; Radium | 2013 |
Future directions from past experience: a century of prostate radiotherapy.
Topics: Bone Neoplasms; Brachytherapy; History, 20th Century; History, 21st Century; Humans; Male; Prostate; Prostatic Neoplasms; Proton Therapy; Radioisotopes; Radiotherapy, Adjuvant; Radium; Salvage Therapy | 2014 |
Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium.
Topics: Bone Neoplasms; Combined Modality Therapy; Humans; Neoplasm Metastasis; Radioisotopes; Radiopharmaceuticals; Radium; Rhenium | 2014 |
Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride.
Topics: Alpha Particles; Animals; Antineoplastic Agents; Bone Neoplasms; Humans; Neoplasm Metastasis; Neoplasms; Organometallic Compounds; Organophosphorus Compounds; Pain Management; Radioisotopes; Radiometry; Radiopharmaceuticals; Radium; Strontium | 2014 |
[Bone metastases treated with radiopharmaceuticals].
Topics: Analgesics; Bone Neoplasms; Breast Neoplasms; Female; Humans; Male; Organometallic Compounds; Organophosphorus Compounds; Pain; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Strontium; Strontium Radioisotopes | 2013 |
[Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
Topics: Alpha Particles; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Cooperative Behavior; Dose-Response Relationship, Radiation; Humans; Interdisciplinary Communication; Male; Palliative Care; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate | 2014 |
Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Survival Rate | 2014 |
Practical guide to the use of radium 223 dichloride.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Treatment Outcome | 2014 |
Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2014 |
Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Lung Neoplasms; Molecular Targeted Therapy; Organometallic Compounds; Organophosphorus Compounds; Osteosarcoma; Radionuclide Imaging; Radiopharmaceuticals; Radium; Technetium Tc 99m Medronate | 2014 |
Pathologic fracture in patients with metastatic prostate cancer.
Topics: Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Zoledronic Acid | 2014 |
Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
Topics: Alpha Particles; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Fractures, Spontaneous; Humans; Male; Pain Management; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium | 2014 |
[Bone-targeted treatment in prostate cancer].
Topics: Alkaline Phosphatase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radium; Randomized Controlled Trials as Topic; RANK Ligand; Treatment Outcome | 2014 |
[Radium-223 treatment of bone metastases from castration-resistant prostate cancer].
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiometry; Radium | 2014 |
[Targeted radionuclide therapy for castration-resistant prostate cancer].
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Strontium Radioisotopes | 2014 |
Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate | 2015 |
Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; United States; United States Food and Drug Administration | 2015 |
Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
Topics: Antineoplastic Agents; Attitude of Health Personnel; Bone Neoplasms; Clinical Trials as Topic; Humans; Male; Patient Education as Topic; Patient Selection; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Urology | 2015 |
Metabolism and pharmacokinetics of radium-223 in prostate cancer.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Precision Medicine; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Survival Rate | 2015 |
(223)Ra and other bone-targeting radiopharmaceuticals-the translation of radiation biology into clinical practice.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Linear Energy Transfer; Palliative Care; Radiobiology; Radioisotopes; Radiopharmaceuticals; Radium; Translational Research, Biomedical | 2015 |
Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.
Topics: Alpha Particles; Animals; Beta Particles; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Colon; DNA Breaks, Double-Stranded; Female; Gastrointestinal Tract; Half-Life; Humans; Male; Mice; Multiple Myeloma; Neoplasms, Second Primary; Osteogenesis; Osteosarcoma; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiologic Health; Radionuclide Imaging; Radium; Rats; Relative Biological Effectiveness; Tissue Distribution | 2015 |
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Enzyme Inhibitors; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Pain; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Spinal Cord Compression; Zoledronic Acid | 2015 |
Targeting bone metastases in prostate cancer: improving clinical outcome.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Osteoblasts; Osteolysis; Pain; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; Zoledronic Acid | 2015 |
Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Prostatic Neoplasms; Radioisotopes; Radium; Zoledronic Acid | 2015 |
Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects.
Topics: Alkaline Phosphatase; Bone Neoplasms; Clinical Trials as Topic; Humans; Male; Prostatic Neoplasms; Radium | 2015 |
Management of bone metastases in prostate cancer: a review.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Zoledronic Acid | 2015 |
[Nuclear medicine in oncotherapy].
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Bone Neoplasms; Humans; Interdisciplinary Communication; Iodine Radioisotopes; Liver Neoplasms; Medical Oncology; Neuroendocrine Tumors; Nuclear Medicine; Prevalence; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Radium; Receptors, Somatostatin; Thyroid Neoplasms | 2015 |
Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
Topics: Antineoplastic Agents; Bone Neoplasms; Cancer Pain; Etidronic Acid; Humans; Male; Organometallic Compounds; Organophosphorus Compounds; Palliative Care; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic; Strontium; Strontium Radioisotopes | 2016 |
Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Humans; Radium | 2016 |
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
Radium-223 dichloride in clinical practice: a review.
Topics: Bone Neoplasms; Comorbidity; Evidence-Based Medicine; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Radium; Survival Rate; Treatment Outcome | 2016 |
Interim Results From ERADICATE: An Open-Label Phase 2 Study of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Castration-Resistant Prostate Cancer Subjects With Symptomatic Bone Metastases.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Humans; Male; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Treatment Outcome | 2016 |
Radium-223 (Ra-223) Re-Treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC).
Topics: Antineoplastic Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Male; Multicenter Studies as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment; Treatment Outcome | 2016 |
Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases.
Topics: Antineoplastic Agents; Biomarkers; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2016 |
Treatment landscape of metastatic prostate cancer: the role of radium-223.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Radioisotopes; Radium | 2017 |
The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Survival Rate; Treatment Outcome | 2016 |
The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.
Topics: Adipocytes; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bone and Bones; Bone Density Conservation Agents; Bone Marrow Cells; Bone Neoplasms; Carcinoma; Denosumab; Diphosphonates; Humans; Male; Mesenchymal Stem Cells; Molecular Targeted Therapy; Osteoblasts; Osteoclasts; Prostatic Neoplasms; Radioisotopes; Radium; Tumor Microenvironment | 2016 |
Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Humans; Male; Radium | 2016 |
Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer.
Topics: Bone Neoplasms; Economics, Pharmaceutical; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium | 2016 |
Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223.
Topics: Bone Neoplasms; Clinical Trials as Topic; Congresses as Topic; Foundations; Humans; Male; New York City; Prostatic Neoplasms; Radioisotopes; Radium; Research Report | 2017 |
Radium-223 Therapy of Bone Metastases in Prostate Cancer.
Topics: Bone Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Humans; Male; Prostatic Neoplasms; Radium | 2016 |
Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Topics: Absorptiometry, Photon; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Evidence-Based Medicine; Fractures, Bone; Humans; Imidazoles; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer.
Topics: Alpha Particles; Animals; Bone Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Neoplasms; Quality of Life; Radiopharmaceuticals; Radium; Survival Rate | 2009 |
[Encounter of cancer cells with bone. Management of bone metastasis arising from prostate cancer].
Topics: Antibodies, Monoclonal; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Evidence-Based Medicine; Humans; Imidazoles; Male; Molecular Targeted Therapy; NF-kappa B; Prostatic Neoplasms; Radioisotopes; Radium; Receptor Activator of Nuclear Factor-kappa B; Strontium; Zoledronic Acid | 2011 |
Clinical dosimetry in the treatment of bone tumors: old and new agents.
Topics: Bone Neoplasms; Humans; Pain; Palliative Care; Phosphorus Radioisotopes; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radium; Rhenium; Samarium; Strontium Radioisotopes; Tin Radioisotopes | 2011 |
Novel molecular targets for the therapy of castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstadienes; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Neoplasms; Cancer Vaccines; Carcinoma; Clinical Trials, Phase III as Topic; Clusterin; Dasatinib; Denosumab; Humans; Ipilimumab; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Pyridines; Pyrimidines; Quinolines; Quinolones; Radium; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Taxoids; Thiazoles; Tissue Extracts; Treatment Outcome; Vaccines, Synthetic | 2012 |
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Dose-Response Relationship, Radiation; Double-Blind Method; Humans; Male; Pain; Palliative Care; Prostatic Neoplasms; Radium; Survival Analysis | 2012 |
Progress in the treatment of bone metastases in cancer patients.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Male; Prostatic Neoplasms; Quality of Life; Radium; Survival Rate | 2012 |
Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.
Topics: Alpha Particles; Bone Neoplasms; Clinical Trials as Topic; Humans; Male; Prostatic Neoplasms; Radiation Protection; Radiopharmaceuticals; Radium | 2012 |
Use of radionuclides in metastatic prostate cancer: pain relief and beyond.
Topics: Bone Neoplasms; Humans; Male; Men's Health; Pain; Palliative Care; Prostatic Neoplasms; Radioisotopes; Radium; Rhenium; Samarium; Strontium | 2012 |
Radium in the environment: exposure pathways and health effects.
Topics: Bone Neoplasms; Environmental Exposure; Environmental Pollutants; Humans; Leukemia; Neoplasms; Occupational Exposure; Radiation Dosage; Radioactive Pollutants; Radium; Risk Factors | 2012 |
[Radionuclide therapy for the treatment of skeletal metastases of urological malignancies: a forgotten therapy?].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diphosphonates; Germany; Guideline Adherence; Humans; Organometallic Compounds; Organophosphorus Compounds; Palliative Care; Radioisotopes; Radium; Spinal Cord Compression; Spinal Neoplasms; Strontium; Survival Rate; Urologic Neoplasms | 2012 |
New and emerging therapies for bone metastases in genitourinary cancers.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Prospective Studies; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic; RANK Ligand; Urinary Bladder Neoplasms; Urogenital Neoplasms; Urothelium; Zoledronic Acid | 2013 |
Radium-223 for the treatment of prostate cancer.
Topics: Bone Neoplasms; Clinical Trials, Phase III as Topic; Humans; Male; Prostatic Neoplasms; Radium | 2013 |
Quantitative comparisons of cancer induction in humans by internally deposited radionuclides and external radiation.
Topics: Animals; Bone Neoplasms; Humans; Leukemia, Radiation-Induced; Liver Neoplasms; Lung Neoplasms; Neoplasms, Radiation-Induced; Plutonium; Radium; Radon; Thorium Dioxide | 2003 |
Target cells in internal dosimetry.
Topics: Bone Neoplasms; Humans; Neoplasms, Radiation-Induced; Organ Specificity; Osteosarcoma; Radiation Dosage; Radioactive Pollutants; Radiometry; Radium | 2003 |
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
Topics: Alpha Particles; Animals; Bone Neoplasms; Breast Neoplasms; Female; Humans; Male; Prostatic Neoplasms; Radiation Dosage; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Radiotherapy, Adjuvant; Radium; Randomized Controlled Trials as Topic | 2006 |
Pathology of radium-induced bone tumors: new aspects of histopathology and histogenesis.
Topics: Bone Neoplasms; Humans; Neoplasms, Radiation-Induced; Radium; Sarcoma | 1999 |
Review of 239Pu and 226Ra effects in beagles.
Topics: Animals; Bone and Bones; Bone Neoplasms; Dogs; Female; Fractures, Bone; Male; Neoplasms, Radiation-Induced; Plutonium; Radiation Injuries; Radium; Soft Tissue Injuries | 2001 |
Radiation-induced sarcomas of bone.
Topics: Animals; Bone Neoplasms; Humans; Neoplasms, Radiation-Induced; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Radium; Risk; Sarcoma; Spondylitis, Ankylosing | 1979 |
Hazards of plutonium with special reference to the skeleton.
Topics: Animals; Body Burden; Bone and Bones; Bone Marrow; Bone Marrow Cells; Bone Neoplasms; Dose-Response Relationship, Radiation; Humans; Leukemia, Myeloid; Maximum Allowable Concentration; Models, Biological; Osteosarcoma; Plutonium; Radiation Effects; Radium | 1976 |
Bone tumor induction after incorporation of short-lived radionuclides.
Topics: Animals; Bone Neoplasms; Lutetium; Mice; Neoplasms, Radiation-Induced; Radium; Thorium | 1991 |
1987 Douglas Lea memorial lecture. Particle dosimetry in bone and the toxicity of bone-seeking radionuclides.
Topics: Bone and Bones; Bone Neoplasms; Densitometry; Female; Humans; Leukemia, Radiation-Induced; Male; Neoplasms, Radiation-Induced; Occupational Diseases; Radiation Dosage; Radioisotopes; Radionuclide Imaging; Radium; Strontium | 1988 |
[The combined action of ionizing radiation and carcinogens].
Topics: Animals; Benz(a)Anthracenes; Bone Neoplasms; Carbon Tetrachloride Poisoning; Carcinogens; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Chemical and Drug Induced Liver Injury; Cobalt Isotopes; Fibrosarcoma; Fluorenes; Gold Isotopes; Guinea Pigs; Liver Neoplasms; Methylcholanthrene; Methylthiouracil; Mice; Neoplasms, Radiation-Induced; Nitrosamines; Osteosarcoma; p-Dimethylaminoazobenzene; Papilloma; Phosphorus Isotopes; Precancerous Conditions; Radiation Injuries, Experimental; Radium; Sarcoma, Experimental; Time Factors; Urethane; Yttrium Isotopes | 1969 |
Late neoplastic changes following medical irradiation.
Topics: Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Chromosomes; Cranial Sinuses; Female; Fetus; Fluoroscopy; Gastrointestinal Neoplasms; Humans; Leukemia, Radiation-Induced; Liver Neoplasms; Male; Mastitis; Neoplasms, Radiation-Induced; Pregnancy; Radiation Genetics; Radiotherapy; Radiotherapy Dosage; Radium; Thorium Dioxide; Time Factors; Uterine Hemorrhage; Uterine Neoplasms | 1972 |
Cancer induction in man from internal radioactivity.
Topics: Bone Neoplasms; Contrast Media; Germany; Humans; Iodine Radioisotopes; Leukemia, Radiation-Induced; Liver Neoplasms; Lung Neoplasms; Mining; Neoplasms, Radiation-Induced; Pacific Islands; Paranasal Sinus Neoplasms; Phosphorus Radioisotopes; Polycythemia Vera; Radioactive Fallout; Radiotherapy; Radium; Radon; Spondylitis, Ankylosing; Thorium; Thorium Dioxide; Thyroid Neoplasms; United States; Uranium | 1973 |
50 trial(s) available for radium and Bone Neoplasms
Article | Year |
---|---|
Topics: Adolescent; Adult; Bone Neoplasms; Female; Fluorine Radioisotopes; Humans; Lung Neoplasms; Neoplasm Metastasis; Osteoblastoma; Osteosarcoma; Positron Emission Tomography Computed Tomography; Radioisotopes; Radium; Sodium Fluoride | 2021 |
A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases.
Topics: Bone Neoplasms; Cancer Pain; Humans; Male; Pentetic Acid; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium | 2022 |
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial.
Topics: Abiraterone Acetate; Androgen Antagonists; Benzamides; Bone Neoplasms; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Receptors, Androgen | 2022 |
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response.
Topics: Bone Neoplasms; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2023 |
Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Disease Progression; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate | 2019 |
A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Neoplasms; Disease-Free Survival; Double-Blind Method; Fractures, Bone; Humans; Male; Middle Aged; Placebos; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome | 2020 |
Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer.
Topics: Adult; Aged; Alpha Particles; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Neoplasms; Breast; Breast Neoplasms; Chemoradiotherapy; Denosumab; Female; Fulvestrant; Humans; Injections, Intravenous; Middle Aged; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Radioisotopes; Radium; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2020 |
Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Chemoradiotherapy; Collagen Type I; Humans; Male; Middle Aged; Nitriles; Peptides; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Rate | 2020 |
CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Capecitabine; Case-Control Studies; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Radioisotopes; Radium; Safety; Treatment Outcome | 2020 |
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2020 |
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
Topics: Adult; Aged; Aged, 80 and over; Animals; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Male; Middle Aged; Progression-Free Survival; Prostatic Neoplasms; Radioisotopes; Radiosurgery; Radium; Randomized Controlled Trials as Topic; Young Adult | 2020 |
Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 study.
Topics: Bone Neoplasms; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2021 |
Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223.
Topics: Bone Neoplasms; Fractures, Bone; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Whole Body Imaging | 2021 |
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Chemoradiotherapy; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate | 2021 |
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
Topics: Aged; Alkaline Phosphatase; Anemia; Asian People; Bone Neoplasms; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Thrombocytopenia; Treatment Outcome | 2017 |
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents; Bone Neoplasms; Humans; Lymphocyte Count; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2018 |
Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Neoplasms; Humans; Kallikreins; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Re-Irradiation | 2017 |
Radium-223 international early access program: results from the Spanish subset.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Disease Progression; Disease-Free Survival; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Spain | 2018 |
Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study.
Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Paclitaxel; Radium; Safety | 2019 |
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2019 |
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.
Topics: Adolescent; Adult; Aged; Alpha Particles; Bone Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Osteosarcoma; Positron Emission Tomography Computed Tomography; Prognosis; Radioisotopes; Radium; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome; Young Adult | 2019 |
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Abiraterone Acetate; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Double-Blind Method; Fractures, Bone; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Topics: Administration, Intravenous; Aged; Anemia; Bone Neoplasms; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radiation Injuries; Radioisotopes; Radium | 2019 |
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
Topics: Aged; Alkaline Phosphatase; Biomarkers, Tumor; Biopsy; Bone and Bones; Bone Neoplasms; Cadherins; Core Binding Factor Alpha 1 Subunit; Disease Progression; Gene Expression; Humans; Male; Molecular Targeted Therapy; Neoplastic Cells, Circulating; Osteonectin; Osteopontin; Prostate; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Analysis; Tumor Microenvironment | 2019 |
Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Rate; Treatment Outcome | 2019 |
Compartmental Model for
Topics: Alpha Particles; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Humans; Intestine, Large; Intestine, Small; Male; Models, Biological; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2019 |
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Dose-Response Relationship, Radiation; Endpoint Determination; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Tissue Distribution | 2013 |
Alpha emitter radium-223 and survival in metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Double-Blind Method; Humans; Isotopes; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms; Radium | 2013 |
Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
Topics: Aged; Animals; Bone Neoplasms; Double-Blind Method; Drug Approval; Humans; Kaplan-Meier Estimate; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; United States; United States Food and Drug Administration | 2014 |
Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Alpha Particles; Antineoplastic Agents; Body Weight; Bone and Bones; Bone Neoplasms; Chlorides; Dose-Response Relationship, Radiation; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radiation Protection; Radioisotopes; Radiopharmaceuticals; Radium; Time Factors; Treatment Outcome | 2014 |
A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease.
Topics: Aged; Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Female; Humans; Middle Aged; Peptides; Radioisotopes; Radium; Treatment Outcome | 2014 |
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium | 2014 |
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPC
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2014 |
Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Neoplasms; Bone Remodeling; Collagen Type I; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Staging; Peptides; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases.
Topics: Aged; Body Burden; Bone Neoplasms; Humans; Male; Metabolic Clearance Rate; Middle Aged; Organ Specificity; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radioisotopes; Radiopharmaceuticals; Radium; Tissue Distribution; Treatment Outcome; Whole-Body Counting | 2015 |
Haematopoietic toxicity of radium-223 in patients with high skeletal tumour burden.
Topics: Bone Marrow Diseases; Bone Neoplasms; Female; Humans; Male; Radiation Injuries; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Radium; Treatment Outcome | 2015 |
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Standard of Care; Taxoids; Treatment Outcome | 2016 |
Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Placebos; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases.
Topics: Aged; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radioisotopes; Radiometry; Radiotherapy Dosage; Radium; Tissue Distribution | 2016 |
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Double-Blind Method; Drug Monitoring; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Analysis; Symptom Assessment; Treatment Outcome | 2016 |
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoradiotherapy; Follow-Up Studies; Humans; Male; Neoplasm Grading; Neoplasm Staging; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate | 2016 |
Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Double-Blind Method; Humans; Incidence; Male; Middle Aged; Neutropenia; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Risk Factors; Thrombocytopenia | 2017 |
Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Double-Blind Method; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium | 2017 |
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Dose-Response Relationship, Radiation; Double-Blind Method; Humans; Male; Pain; Palliative Care; Prostatic Neoplasms; Radium; Survival Analysis | 2012 |
A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Alpha Particles; Bone Neoplasms; Dose-Response Relationship, Radiation; Double-Blind Method; Drug Administration Schedule; Humans; Kallikreins; Male; Middle Aged; Pain Measurement; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome | 2013 |
Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review.
Topics: Adenocarcinoma; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Drug Resistance, Neoplasm; Humans; Male; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radium | 2012 |
First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Alpha Particles; Bone Neoplasms; Breast Neoplasms; Diarrhea; Dose-Response Relationship, Radiation; Fatigue; Female; Follow-Up Studies; Humans; Injections, Intravenous; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Pain; Prostatic Neoplasms; Radionuclide Imaging; Radium; Treatment Outcome; Vomiting | 2005 |
[186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Pain; Pain Measurement; Palliative Care; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Treatment Outcome | 2006 |
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Neoplasms; Double-Blind Method; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Placebos; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radium; Survival Rate | 2007 |
323 other study(ies) available for radium and Bone Neoplasms
Article | Year |
---|---|
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Benzamides; Bone Neoplasms; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2022 |
[Exploratory Analysis Results from Post-marketing Surveillance Study of Radium-223 in Japanese Patients with Castration-resistant Prostate Cancer and Bone Metastases: Subgroup Analysis by Age].
Topics: Aged; Bone Neoplasms; Humans; Japan; Laboratories, Clinical; Male; Product Surveillance, Postmarketing; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2021 |
A qualitative research study in Japan investigating patients' experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Cost of Illness; Decision Making; Humans; Interviews as Topic; Japan; Male; Middle Aged; Physicians; Prostatic Neoplasms, Castration-Resistant; Qualitative Research; Quality of Life; Radium | 2021 |
Graphene Quantum Dots for Molecular Radiotherapy: Radiolabeled Graphene Quantum Dots with Radium (
Topics: Bone Neoplasms; Graphite; Humans; Osteosarcoma; Quantum Dots; Radium | 2021 |
mRNA and small RNA gene expression changes in peripheral blood to detect internal Ra-223 exposure.
Topics: Bone Neoplasms; Gene Expression; Humans; Male; MicroRNAs; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; RNA, Messenger | 2022 |
Radium-223 Dichloride in Peritoneal Dialysate Following Treatment of Metastatic Castration-resistant Prostate Cancer.
Topics: Bone Neoplasms; Dialysis Solutions; Humans; Male; Peritoneal Dialysis; Prostatic Neoplasms, Castration-Resistant; Radium | 2022 |
Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Case-Control Studies; Chemoradiotherapy; Ethinyl Estradiol; Humans; Japan; Kallikreins; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Analysis; Treatment Outcome | 2022 |
Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan.
Topics: Alkaline Phosphatase; Bone Neoplasms; Humans; Male; Pain; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Retrospective Studies; Taiwan; Tertiary Care Centers; Treatment Outcome | 2022 |
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
Topics: Aged; Bone Neoplasms; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retrospective Studies; Treatment Outcome | 2022 |
[
Topics: Bone Neoplasms; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Carriers; Humans; Micelles; Nanoparticles; Osteosarcoma; Particle Size; Poloxamer; Radioisotopes; Radiopharmaceuticals; Radium | 2022 |
Radium-223 in the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Female; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2022 |
Ocular complications with the use of radium-223: a case series.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radium | 2022 |
The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Topics: Bone Neoplasms; Humans; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2022 |
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy.
Topics: Alkaline Phosphatase; Analgesics, Opioid; Bone Neoplasms; Hemoglobins; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Psychological Distress; Quality of Life; Radium | 2023 |
Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study.
Topics: Bone Neoplasms; Clinical Trials as Topic; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2022 |
S-values for radium-223 and absorbed doses estimates for
Topics: Bismuth; Body Weight; Bone Neoplasms; Female; Humans; Male; Monte Carlo Method; Phantoms, Imaging; Polonium; Radioisotopes; Radium; Radon; Thallium | 2022 |
[Retrospective practice-related care research study on therapy of mCPRC with radium-223 dichloride].
Topics: Bone Neoplasms; Fractures, Bone; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2022 |
Real World Outcomes in Patients With Metastatic, Castration-Resistant Prostate Cancer Treated With Radium-223 in Routine Clinical Practice in Sweden.
Topics: Bone Neoplasms; Fractures, Bone; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Sweden | 2023 |
Efficacy and Safety of Radium-223 for Castration-resistant Prostate Cancer With Bone Metastasis Before and After Docetaxel.
Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2022 |
Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study.
Topics: Anemia; Bone Neoplasms; Female; Humans; Male; Pain; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2023 |
Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) T
Topics: Bone Neoplasms; East Asian People; Humans; Male; Nomograms; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2023 |
Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters.
Topics: Bone and Bones; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2023 |
The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
Nano-hydroxyapatite radiolabeled with radium dichloride [
Topics: Bone Neoplasms; Humans; Nanostructures; Osteosarcoma; Radiopharmaceuticals; Radium | 2023 |
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model.
Topics: Benzamides; Bone Neoplasms; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
Sarcopenia in Men With Bone-Predominant Metastatic Castration-Resistant Prostate Cancer Undergoing Ra-223 Therapy.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Sarcopenia | 2023 |
Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2023 |
Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2023 |
Editorial Comment to Bone-modifying agents are protective for symptomatic skeletal events in radium-223 treatment.
Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
Radium-223 and bone metastatic disease: still more to learn.
Topics: Bone Neoplasms; Humans; Magnetic Resonance Imaging; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial.
Topics: Abiraterone Acetate; Bone Density; Bone Neoplasms; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Radioisotope Therapy of Bone Metastases-A Nuclear Medicine Perspective.
Topics: Bone Neoplasms; Humans; Nuclear Medicine; Radiopharmaceuticals; Radium | 2019 |
Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Chemoradiotherapy, Adjuvant; Disease Progression; Follow-Up Studies; Humans; Male; Neoplasm Grading; Prognosis; Prostate; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Survival Analysis; Treatment Outcome | 2019 |
Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Software; Survival Analysis | 2019 |
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Registries; Taxoids | 2020 |
Three years' clinical practice of Radium-223 therapy in patients with symptomatic bone metastases from metastatic castrate-resistant prostate cancer: a single-centre experience.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
The Relationship Between Total Lesion Activity on
Topics: Aged; Aged, 80 and over; Alpha Particles; Bone and Bones; Bone Neoplasms; Choline; Feasibility Studies; Fluorine Radioisotopes; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retrospective Studies; Treatment Outcome | 2020 |
Preclinical Single Photon Emission Computed Tomography of Alpha Particle-Emitting Radium-223.
Topics: Animals; Autoradiography; Bone and Bones; Bone Neoplasms; Humans; Male; Mice; Models, Animal; Phantoms, Imaging; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Tissue Distribution; Tomography, Emission-Computed, Single-Photon | 2020 |
Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice.
Topics: Androgen Antagonists; Bone Neoplasms; Humans; Longitudinal Studies; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2020 |
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223.
Topics: Abiraterone Acetate; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2020 |
Clinical aspects of mCRPC management in patients treated with radium-223.
Topics: Aged; Alkaline Phosphatase; Anemia; Bone Neoplasms; Cohort Studies; Hemoglobins; Humans; Kaplan-Meier Estimate; Male; Pain; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium | 2020 |
A National Multicenter Study on overall survival in elderly metastatic castrate-resistant prostate cancer patients treated with Radium-223.
Topics: Aged; Bone Neoplasms; Humans; Italy; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2021 |
In situ Generated
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Humans; Lead Radioisotopes; Ligands; Male; Mice; Mice, Nude; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Thorium | 2020 |
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Denosumab; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Databases, Factual; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retrospective Studies; Survival Rate; Treatment Outcome | 2020 |
ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223.
Topics: Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Humans; Radioisotopes; Radium | 2020 |
An agent-based model of prostate Cancer bone metastasis progression and response to Radium223.
Topics: Animals; Bone Neoplasms; Brachytherapy; Cell Line, Tumor; Computer Simulation; Disease Progression; Humans; Intravital Microscopy; Male; Mice; Microscopy, Fluorescence; Models, Biological; Prostatic Neoplasms; Radiation Tolerance; Radium; Tibia; Xenograft Model Antitumor Assays | 2020 |
Typical Acute Traumatic Fracture Healing in an 83-Year-Old Man Undergoing 223Ra Treatment for Prostatic Cancer Bone Metastases.
Topics: Aged, 80 and over; Bone Neoplasms; Fracture Healing; Humans; Male; Prostatic Neoplasms; Radium; Tibial Fractures | 2020 |
Bone scan index can be a useful biomarker of survival outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223.
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Feasibility Studies; Humans; Image Interpretation, Computer-Assisted; Japan; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Neural Networks, Computer; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radionuclide Imaging; Radium; Retrospective Studies; Risk Assessment; Tomography, X-Ray Computed; Tumor Burden | 2019 |
Radium-223 in mCPRC patients: a large real-life Italian multicenter study.
Topics: Bone Neoplasms; Humans; Italy; Quality of Life; Radium; Treatment Outcome | 2022 |
Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center.
Topics: Aged; Bone Neoplasms; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome; United States | 2021 |
Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
Topics: Aged; Bone Neoplasms; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2021 |
Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy.
Topics: Aged; Bone Neoplasms; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radium; Retrospective Studies; Surveys and Questionnaires | 2020 |
Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Clinical Decision-Making; Humans; Male; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors | 2020 |
Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC.
Topics: Aged; Bone Neoplasms; Cancer Pain; Humans; Male; Palliative Care; Prostatic Neoplasms, Castration-Resistant; Radium; Retreatment | 2020 |
Comment on: 'Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer' by De Vincentis et al.
Topics: Bone Neoplasms; DNA Damage; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2021 |
Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Bone Neoplasms; Chemoradiotherapy; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Neoplasm Grading; Patient Selection; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Retrospective Studies; Survival Analysis; Treatment Outcome | 2021 |
Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status
Topics: Androgens; Bone Neoplasms; Humans; Japan; Male; Product Surveillance, Postmarketing; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2021 |
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.
Topics: Alkaline Phosphatase; Biomarkers; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2021 |
Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
Topics: Aged; Androstenes; Benzamides; Bone Neoplasms; Combined Modality Therapy; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Rate; Veterans | 2021 |
Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Exosomes; Extracellular Vesicles; Gene Expression; Gene Expression Profiling; Humans; Immune Checkpoint Proteins; Male; Mice; Prostatic Neoplasms; Radiopharmaceuticals; Radium; RNA; Survival Rate; Tumor Microenvironment | 2021 |
Kinetics of radium-223 and its effects on survival, proliferation and DNA damage in lymph-node and bone metastatic prostate cancer cell lines.
Topics: Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Damage; Humans; Kinetics; Lymphatic Metastasis; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2021 |
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Retrospective Studies; Survival Rate; Taxoids | 2021 |
Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
Topics: Academic Medical Centers; Aged; Aged, 80 and over; Bone Neoplasms; Community Health Services; Disease Management; Follow-Up Studies; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate; Treatment Outcome | 2021 |
Radium Ra 223 Alpha Therapy for Prostate Cancer Bone Metastasis.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Radium | 2021 |
Extraction of
Topics: Blood Component Removal; Bone Neoplasms; Dialysis Solutions; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radiation Protection; Radioisotopes; Radiopharmaceuticals; Radium; Renal Dialysis; Treatment Outcome | 2017 |
Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy.
Topics: Aged; Biomarkers; Blood Cell Count; Bone Neoplasms; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Off-Label Use; Prostatectomy; Prostatic Neoplasms; Radioisotopes; Radium; Single Photon Emission Computed Tomography Computed Tomography | 2017 |
223Ra-dichloride response in a patient with Paget disease and bone metastases secondary to castration-resistant prostate cancer.
Topics: Aged; Bone Neoplasms; Humans; Male; Osteitis Deformans; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium | 2017 |
Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed?
Topics: Aged; Bone Neoplasms; Choline; Humans; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome | 2017 |
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Hematologic Tests; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Tumor Burden | 2018 |
Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.
Topics: Bone Neoplasms; Clinical Decision-Making; Combined Modality Therapy; Disease Progression; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Prostatic Neoplasms, Castration-Resistant; Radium; Symptom Assessment; Treatment Outcome | 2017 |
On the
Topics: Bone Neoplasms; Fluorides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Positron-Emission Tomography; Radiopharmaceuticals; Radium; Tomography, X-Ray Computed | 2018 |
Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Bone Neoplasms; CD8-Positive T-Lymphocytes; Humans; Interferon-gamma; Interleukin-13; Male; Middle Aged; Prednisone; Programmed Cell Death 1 Receptor; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome; Tumor Necrosis Factor-alpha | 2018 |
223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases: Lessons from Daily Practice.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2018 |
High-Energy Collimator Is Preferable to Medium-Energy Collimator for Evaluating 223Ra Uptake in Bone Metastasis at 2 Weeks Postinjection.
Topics: Aged, 80 and over; Biological Transport; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radionuclide Imaging; Radium | 2018 |
Lymph Node Response in a Patient With Metastatic Castration-resistant Prostate Cancer Treated With Radium-223.
Topics: Aged; Antigens, Surface; Bone Neoplasms; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Humans; Lymph Nodes; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Analysis; Treatment Outcome | 2018 |
Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Whole-Body Counting | 2018 |
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
Topics: Bone Neoplasms; Europe; Humans; Male; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2018 |
The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Italy; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Retrospective Studies; Taxoids | 2018 |
Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Bone and Bones; Bone Neoplasms; Humans; Male; Middle Aged; Prostatic Neoplasms; Radium; Tumor Burden | 2018 |
A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; ROC Curve; Survival Analysis | 2018 |
DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223.
Topics: Aged; Biomarkers, Tumor; Bone Neoplasms; DNA Repair; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Sequence Analysis, DNA; Treatment Outcome | 2018 |
Bone radionuclide therapy and increased survival with radium-223 is the way to go for nuclear medicine: the offer that oncologists cannot refuse.
Topics: Bone Neoplasms; Humans; Nuclear Medicine; Oncologists; Radioisotopes; Radionuclide Imaging; Radium | 2018 |
The Pseudo-Pelger huët Cell as a Retrospective Dosimeter: Analysis of a Radium Dial Painter Cohort.
Topics: Adolescent; Adult; Biological Assay; Bone Neoplasms; Female; Humans; Male; Mastoid; Neoplasms, Radiation-Induced; Occupational Diseases; Osteosarcoma; Pelger-Huet Anomaly; Radiation Exposure; Radiation Injuries; Radiation Monitoring; Radium; Retrospective Studies; Young Adult | 2019 |
Fatal Intracranial Hemorrhage Due to Thrombocytopenia in a Patient With Castration-Resistant Prostate Cancer Showing Extensive Bone Uptake of Injected 223Ra Dichloride.
Topics: Bone Neoplasms; Humans; Intracranial Hemorrhages; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Thrombocytopenia; Tomography, Emission-Computed, Single-Photon | 2018 |
Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223?
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Denosumab; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radionuclide Imaging; Radium; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.
Topics: Aged; Aged, 80 and over; Blood; Bone Neoplasms; Choline; Humans; Male; Middle Aged; Pilot Projects; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radium | 2018 |
Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Diphosphonates; Disease Progression; Fatal Outcome; Humans; Male; Prostatic Neoplasms; Radium | 2018 |
Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Neoplasms; Health Status; Hemoglobins; Humans; Lymphocyte Count; Male; Middle Aged; Neutrophils; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate | 2018 |
Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide.
Topics: Abiraterone Acetate; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radium; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.
Topics: Bone Neoplasms; Fluorides; Fluorine Radioisotopes; Humans; Male; Positron-Emission Tomography; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium | 2018 |
Hungry bone syndrome secondary to prostate cancer successfully treated with radium therapy.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Calcium Carbonate; Ergocalciferols; Humans; Hypocalcemia; Male; Middle Aged; Prostatic Neoplasms; Radioisotopes; Radium; Whole Body Imaging | 2018 |
Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Cell Count; Disease Progression; Follow-Up Studies; Humans; Injections, Intravenous; Male; Neoplastic Cells, Circulating; Prognosis; Progression-Free Survival; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiotherapy Dosage; Radium | 2018 |
Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Topics: Aged; Alkaline Phosphatase; Biomarkers, Tumor; Bone Neoplasms; Germ-Line Mutation; Humans; Male; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Recombinational DNA Repair; Survival Analysis; Treatment Outcome | 2019 |
[Radium 223 in castration resistant prostate cancer.]
Topics: Antineoplastic Agents; Bone Neoplasms; Forecasting; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2018 |
Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.
Topics: Androstenes; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Chemoradiotherapy; Follow-Up Studies; Humans; Male; Nitriles; Pain Management; Palliative Care; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Time Factors | 2019 |
Mechanistic Modeling of Radium-223 Treatment of Bone Metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Radiation; Humans; Kaplan-Meier Estimate; Models, Biological; Radioisotopes; Radium; Time Factors; Tumor Burden | 2019 |
Radium 223-Mediated Zonal Cytotoxicity of Prostate Cancer in Bone.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Radiation; Humans; Male; Mice; Microscopy, Fluorescence, Multiphoton; Prostatic Neoplasms; Radium; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Culture Techniques; Cell Proliferation; Docetaxel; Drug Screening Assays, Antitumor; Humans; Male; Mice, SCID; PC-3 Cells; Prostatic Neoplasms; Radium; Spheroids, Cellular; Tumor Cells, Cultured; Tumor Microenvironment | 2019 |
Assessment of the radiation absorbed dose produced by
Topics: Actinium; Antigens, Surface; Bone Neoplasms; Cell Line, Tumor; Cell Nucleus; Computer Simulation; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Models, Biological; Monte Carlo Method; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Radium; Tumor Microenvironment | 2019 |
Updated:
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2019 |
Bone scan index as metastatic bone disease quantifier and predictor of radium-223-dichloride biochemical response.
Topics: Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Radioisotopes; Radium; Retrospective Studies; Treatment Outcome | 2019 |
Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome; Zoledronic Acid | 2019 |
Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Disease Progression; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Soft Tissue Neoplasms; Treatment Outcome | 2019 |
Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome | 2019 |
No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Cancer Pain; Humans; Male; Middle Aged; Pain Measurement; Prostatic Neoplasms, Castration-Resistant; Psychological Distress; Quality of Life; Radium; Retrospective Studies | 2019 |
Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial.
Topics: Abiraterone Acetate; Bone Neoplasms; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cachexia; Cell Proliferation; Diphosphonates; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA, Neoplasm; Doxorubicin; Female; Imidazoles; Kaplan-Meier Estimate; Mice; Osteoblasts; Osteoclasts; Radioisotopes; Radium; Stem Cells; Tumor Cells, Cultured; Zoledronic Acid | 2013 |
FDA approves radiopharmaceutical for metastatic prostate cancer.
Topics: Bone Neoplasms; Clinical Trials as Topic; Drug Approval; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radium; United States; United States Food and Drug Administration | 2013 |
Fighting prostate cancer with radium-223--not your Madame's isotope.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Radium | 2013 |
New treatment option: 223Ra chloride, the first approved unsealed α-emitting radiopharmaceutical.
Topics: Aged; Bone Neoplasms; Drug Approval; Humans; Male; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radium | 2013 |
Radium Ra 223 dichloride in castration-resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Male; Orchiectomy; Prostatic Neoplasms; Radioisotopes; Radium; Survival Rate | 2013 |
Radium - 223 (Xofigo) for prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Drug Approval; Humans; Male; Prostatic Neoplasms; Radioisotopes; Radium; United States; United States Food and Drug Administration | 2013 |
Prostate cancer: radium-223: a new treatment option for bone-metastatic CRPC.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Radium | 2013 |
Radium-223 in prostate cancer.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Radium | 2013 |
Radium-223 in prostate cancer.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Radium | 2013 |
Radium-223 in prostate cancer.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Radium | 2013 |
Prostate cancer, version 1.2014.
Topics: Bone Neoplasms; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Radioisotopes; Radium; Recurrence | 2013 |
Re: alpha emitter radium-223 and survival in metastatic prostate cancer.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Radium | 2014 |
To treat or not to treat, that is the question: the role of bone-targeted therapy in metastatic prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Castration; Denosumab; Diagnosis, Differential; Diphosphonates; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Radium; RANK Ligand | 2014 |
Prostate cancer bone metastases: not so systemic after all.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2014 |
Radium-223 vs EBRT for multiple painful bone metastases: the data favor radium-223.
Topics: Bone Neoplasms; Dose Fractionation, Radiation; Humans; Male; Pain Management; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy; Radium; Risk Assessment | 2014 |
Radium-223 vs EBRT for multiple painful bone metastases: is less more?
Topics: Bone Neoplasms; Dose Fractionation, Radiation; Humans; Male; Pain Management; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy; Radium; Risk Assessment | 2014 |
Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Pain Management; Patient Selection; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium | 2015 |
Radium-223 dichloride for the treatment of metastatic prostate cancer.
Topics: Bone and Bones; Bone Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Male; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic | 2014 |
Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods.
Topics: Algorithms; Beta Particles; Bone Neoplasms; Computer Simulation; DNA; DNA Damage; DNA Repair; Humans; Lutetium; Monte Carlo Method; Neoplasm Metastasis; Palliative Care; Radioisotopes; Radiopharmaceuticals; Radium; Rhenium; Samarium; Strontium Radioisotopes | 2014 |
Effect of docetaxel on safety and efficacy of radium-223.
Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2014 |
Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223.
Topics: Alkaline Phosphatase; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Humans; Male; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiotherapy; Radium; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Targeted radionuclides for prostate cancer bone metastases.
Topics: Bone Neoplasms; Clinical Trials, Phase IV as Topic; Double-Blind Method; Humans; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic | 2015 |
One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Bone Neoplasms; Disease Progression; Humans; Male; Middle Aged; Pain; Pain Measurement; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retrospective Studies; Treatment Outcome | 2015 |
Re: Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2015 |
Real-time scintigraphic assessment of intravenous radium-223 administration for quality control.
Topics: Administration, Intravenous; Alpha Particles; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality Control; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Radium; Retrospective Studies | 2015 |
Determination of photon emission probabilities for the main gamma-rays of ²²³Ra in equilibrium with its progeny.
Topics: Bone Neoplasms; Gamma Rays; Germanium; Half-Life; Humans; Male; Photons; Probability; Prostatic Neoplasms, Castration-Resistant; Radium; Spectrometry, Gamma | 2015 |
Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Humans; Kallikreins; Male; Pain; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Tomography, Emission-Computed; Treatment Outcome | 2015 |
Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2015 |
Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Disease-Free Survival; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Odds Ratio; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Reproducibility of Results; Research Design; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Radium-223: Optimizing Treatment and Research of Osteoblastic Bone Metastasis.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Radium | 2015 |
Radiation Dose and Hazard Assessment of Potential Contamination Events During Use of 223Ra Dichloride in Radionuclide Therapy.
Topics: Air Pollutants, Radioactive; Bone Neoplasms; Humans; Inhalation Exposure; Male; Occupational Exposure; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radiation Injuries; Radioactive Hazard Release; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Radium; Skin | 2015 |
Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
Topics: Adult; Alpha Particles; Biological Transport; Bone Neoplasms; Humans; Kinetics; Male; Organotechnetium Compounds; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiometry; Radium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2016 |
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Brachytherapy; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Treatment Outcome | 2015 |
Palliation of Extensive Metastatic Bone Disease With 223Ra-Dichloride α-Particle Therapy in a Patient With Malignant Hereditary Paraganglioma-Pheochromocytoma Syndrome With SDHB Mutation.
Topics: Adult; Alpha Particles; Bone Neoplasms; Female; Humans; Neoplastic Syndromes, Hereditary; Palliative Care; Paraganglioma; Radioisotopes; Radiopharmaceuticals; Radium; Succinate Dehydrogenase | 2016 |
The timing of radium-223 therapy in castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brachytherapy; Combined Modality Therapy; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment; Time Factors; Treatment Outcome | 2015 |
New developments in metastatic prostate cancer therapy.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Staging; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiotherapy; Radium; Risk Assessment; Taxoids; Therapies, Investigational; United Kingdom | 2015 |
Radium-223 dichloride therapy in breast cancer with osseous metastases.
Topics: Aged; Alkaline Phosphatase; Antigens, Tumor-Associated, Carbohydrate; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Off-Label Use; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Radium; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up.
Topics: Aged; Bone Neoplasms; Chlorides; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radiometry; Radium | 2016 |
Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis.
Topics: Alpha Particles; Animals; Antineoplastic Agents; Autoradiography; Bone Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Tissue Distribution; Tumor Microenvironment; Whole-Body Irradiation | 2016 |
[Good risk/benefit profile of treatment with confirmed alpha emitter].
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2015 |
[Radium dichloride-223 improves symptoms including in the daily clinic].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2015 |
NICE guidance on radium-223 dichloride for hormone-relapsed prostate cancer with bone metastases.
Topics: Aged; Bone Neoplasms; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Risk Assessment; Survival Rate; Treatment Outcome; United Kingdom | 2016 |
Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy.
Topics: Aged; Aged, 80 and over; Bone Marrow; Bone Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Radium; Tomography, X-Ray Computed; Tumor Burden | 2016 |
Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer.
Topics: Aged; Anemia; Antineoplastic Agents; Bone Marrow Diseases; Bone Neoplasms; Compassionate Use Trials; Dipeptides; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Oligopeptides; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Radium; Technetium Tc 99m Medronate | 2016 |
When to initiate treatment with radium-223 in patients with metastatic castration-resistant prostate cancer.
Topics: Biomarkers, Tumor; Bone Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Humans; Male; Neoplasm Metastasis; Patient Selection; Practice Guidelines as Topic; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Time-to-Treatment; Treatment Outcome | 2016 |
Prostate-Specific Antigen Flare Phenomenon During
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium | 2016 |
Dosing, administration, and safety of radium-223: How I do it.
Topics: Antineoplastic Agents; Bone Neoplasms; Canada; Humans; Legislation, Drug; Male; Patient Education as Topic; Patient Selection; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Safety; United States | 2016 |
Updates on radium-223 for castration-resistant prostate cancer presented at the Genitourinary Cancers Symposium, January 7-9, 2016, San Francisco, California.
Topics: Antineoplastic Agents; Bone Neoplasms; Clinical Trials, Phase II as Topic; Congresses as Topic; Health Services; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium | 2016 |
68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Middle Aged; Oligopeptides; Organometallic Compounds; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radium; Treatment Outcome | 2016 |
[Therapy of bone metastases with radium-223. German guidelines].
Topics: Bone Neoplasms; Evidence-Based Medicine; Germany; Nuclear Medicine; Practice Guidelines as Topic; Radiopharmaceuticals; Radiotherapy; Radium; Treatment Outcome | 2016 |
Radium-223 in prostate cancer: emitting the right signals.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Radium | 2016 |
Prostate cancer: Radium-223 safe in combination.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2016 |
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Topics: Abdominal Neoplasms; Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Topics: Aged; Bone Neoplasms; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Oligopeptides; Organometallic Compounds; Positron-Emission Tomography; Prognosis; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Image-Guided; Radium; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2017 |
Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation.
Topics: Bone Neoplasms; BRCA2 Protein; Humans; Male; Middle Aged; Mutation; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Treatment Outcome | 2017 |
Evaluation of bone metastases by 18F-choline PET/CT in a patient with castration-resistant prostate cancer treated with radium-223.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Choline; Fluorine Radioisotopes; Humans; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radium | 2017 |
Acute Myeloid Leukemia After Radium-223 Therapy: Case Report.
Topics: Aged; Bone Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Prostatic Neoplasms, Castration-Resistant; Radium | 2017 |
[Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Topics: Bone Neoplasms; Dose-Response Relationship, Radiation; Evidence-Based Medicine; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Radium; Symptom Assessment; Treatment Outcome | 2017 |
A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cancer Pain; Humans; Hungary; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Retrospective Studies | 2017 |
Acute Promyelocytic Leukemia After Treatment of Metastatic Castration-Resistant Prostate Cancer With Radium-223.
Topics: Aged; Bone Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Leukemia, Radiation-Induced; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2017 |
223Ra Dichloride Bone-Targeted Therapy in a Case of Metastatic Salivary Duct Carcinoma.
Topics: Aged; Bone Neoplasms; Carcinoma, Ductal; Humans; Male; Radiopharmaceuticals; Radium; Salivary Gland Neoplasms | 2017 |
Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Kallikreins; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Retrospective Studies; Treatment Outcome | 2017 |
Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer.
Topics: Bone Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Neoplastic Stem Cells; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Stromal Cells | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Radium | 2011 |
Radiation-based approaches for therapy and palliation of advanced prostate cancer.
Topics: Alpha Particles; Bone Neoplasms; Dose Fractionation, Radiation; Evidence-Based Medicine; Humans; Male; Organometallic Compounds; Organophosphorus Compounds; Palliative Care; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic; Strontium Radioisotopes; Treatment Outcome | 2012 |
Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases.
Topics: Alpha Particles; Bone Neoplasms; Chlorides; Feasibility Studies; Gamma Cameras; Humans; Phantoms, Imaging; Radioisotopes; Radium; Treatment Outcome | 2012 |
Radium-223: down to the bone, and less is more.
Topics: Alpha Particles; Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Radiation Protection; Radiopharmaceuticals; Radium | 2012 |
An alpha edge?
Topics: Alpha Particles; Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Radiation Protection; Radiopharmaceuticals; Radium | 2012 |
Molecular radiotherapy.
Topics: Analgesics, Non-Narcotic; Bone Neoplasms; Humans; Iodine Radioisotopes; Lymphoma; Organometallic Compounds; Organophosphorus Compounds; Palliative Care; Radiotherapy; Radium; Strontium Radioisotopes; Synovial Membrane | 2012 |
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Pain Management; Palliative Care; Proportional Hazards Models; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2013 |
Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients.
Topics: Adenocarcinoma; Alpha Particles; Bone Neoplasms; Humans; Kallikreins; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radium | 2013 |
(223)Ra targets skeletal metastases and spares normal tissue.
Topics: Animals; Bone and Bones; Bone Neoplasms; Disease Models, Animal; Humans; Radiation Injuries; Radiotherapy; Radium; Rats; Sensitivity and Specificity | 2002 |
A consistent two-mutation model of bone cancer for two data sets of radium-injected beagles.
Topics: Animals; Bone Neoplasms; Dogs; Dose-Response Relationship, Radiation; Injections; Mutagenesis; Neoplasms, Radiation-Induced; Osteosarcoma; Radiation Dosage; Radium | 2002 |
Is there a difference in radionuclide-induced bone tumor sensitivity between male and female beagles?
Topics: Animals; Bone and Bones; Bone Neoplasms; Dogs; Female; Humans; Linear Models; Male; Neoplasms, Radiation-Induced; Plutonium; Radium; Sex Factors | 1999 |
Radioactivity and the human skeleton.
Topics: Bone and Bones; Bone Neoplasms; Humans; Neoplasms; Radioactivity; Radium | 1958 |
[Radiation induced bone tumors after thorium-X treatment].
Topics: Bone and Bones; Bone Neoplasms; Humans; Neoplasms; Neoplasms, Radiation-Induced; Osteosarcoma; Radiation Injuries; Radium; Sarcoma; Thorium | 1962 |
Development of osteogenic sarcoma in a radium dial painter thirty-seven years after the end of exposure.
Topics: Bone Neoplasms; Femur; Humans; Medical Records; Neoplasms; Occupational Diseases; Osteosarcoma; Radium; Sarcoma; Tibia | 1962 |
THE METABOLISM OF BIOLOGICALLY IMPORTANT RADIONUCLIDES. II. A REVIEW OF SOME FACTORS AFFECTING THE RADIATION DAMAGE TO BONE FROM INGESTED RADIUM.
Topics: Bone Diseases; Bone Neoplasms; Humans; Metabolism; Radiation Injuries; Radioisotopes; Radiometry; Radium | 1964 |
THE CONCENTRATION OF RA-226, RA-228, PB-210, LEAD AND FLUORIDE IN HUMAN BONE FROM INDIVIDUALS WITH AN OSTEOGENIC SARCOMA. ANL-6769.
Topics: Bone and Bones; Bone Neoplasms; Fluorides; Humans; Lead; Metabolism; Neoplasms; Neoplasms, Radiation-Induced; Osteosarcoma; Phosphates; Radioisotopes; Radium; Sarcoma | 1963 |
RADIUM-226, RADIUM-228, LEAD-210, AND FLUORINE IN PERSONS WITH OSTEOGENIC SARCOMA.
Topics: Bone and Bones; Bone Neoplasms; Chemistry Techniques, Analytical; Fluorides; Fluorine; Humans; Lead; Osteosarcoma; Radioisotopes; Radium; Sarcoma | 1964 |
OCCUPATIONAL HAZARD.
Topics: Bone Neoplasms; Connecticut; Femur; Fibrosarcoma; Forearm; Giant Cell Tumors; Humans; Ilium; Knee Joint; Neoplasms; Neoplasms, Radiation-Induced; New Jersey; Occupational Diseases; Osteosarcoma; Osteosclerosis; Pelvic Bones; Radiation Genetics; Radiation Injuries; Radiography; Radium; Sarcoma; Skull; Spine; Thorium | 1964 |
OSTEOGENIC SARCOMA OF THE MANDIBLE. REPORT OF CASE TREATED BY RADIATION AND CHEMOTHERAPY.
Topics: Bone Neoplasms; Cobalt Isotopes; Dactinomycin; Drug Therapy; Humans; Mandible; Mandibular Neoplasms; Melphalan; Methotrexate; Neoplasms; Osteomyelitis; Osteosarcoma; Pathology; Radiography; Radium; Sarcoma | 1964 |
RADIATION-INDUCED CARCINOMA OF THE MASTOID.
Topics: Bone Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Humans; Mastoid; Neoplasms; Neoplasms, Radiation-Induced; Pathology; Photomicrography; Radiography; Radium; Temporal Bone | 1965 |
LONG-TERM EFFECTS OF RADIUM DEPOSITION IN MAN: PROGRESS REPORT. ANL-6839.
Topics: Bone Neoplasms; Humans; Male; Neoplasms; Neoplasms, Radiation-Induced; Radiation; Radiation Injuries; Radium; Research Report; Time | 1965 |
MALIGNANT HEMANGIOENDOTHELIOMA OF BONE: REPORT OF TWO CASES AND REVIEW OF THE LITERATURE.
Topics: Bone Neoplasms; Diagnosis, Differential; Femoral Neoplasms; Hemangioendothelioma; Humans; Neoplasms; Pathology; Radiography; Radium; Radius; Sarcoma; Sarcoma, Ewing; Surgical Procedures, Operative; Ulnar Nerve | 1965 |
Studies of radium in human bone.
Topics: Bone Neoplasms; Humans; Neoplasms; Osteosarcoma; Radium; Sarcoma | 1951 |
[Reports from radium clinics. "Rheumatism" and bone metastases, specifically from breast cancer].
Topics: Bone Neoplasms; Breast; Breast Neoplasms; Humans; Neoplasms; Radium; Rheumatic Diseases | 1950 |
Two-mutation models for bone cancer due to radium, strontium and plutonium.
Topics: Animals; Bone Neoplasms; Dogs; Dose-Response Relationship, Radiation; Models, Genetic; Mutation; Neoplasms, Radiation-Induced; Plutonium; Radium; Strontium | 2004 |
Illinois bone tumor death certificate study.
Topics: Bone and Bones; Bone Neoplasms; Death Certificates; Humans; Illinois; Neoplasms; Radium | 1960 |
Bone cancer risk in mice exposed to 224Ra: protraction effects from promotion.
Topics: Animals; Bone Neoplasms; Female; Mice; Models, Biological; Neoplasms, Radiation-Induced; Osteosarcoma; Radium; Risk Assessment; Thorium | 2005 |
Comments on "Two-mutation models for bone cancer due to radium, strontium and plutonium" by Bijwaard et al. (Radiat. Res. 162, 171-184, 2004).
Topics: Animals; Bone Neoplasms; Dogs; Humans; Models, Biological; Mutation; Osteosarcoma; Plutonium; Radium; Reproducibility of Results; Strontium | 2005 |
Mechanistic models of bone cancer induction by radium and plutonium in animals compared to humans.
Topics: Animals; Bone Neoplasms; Computer Simulation; Dogs; Dose-Response Relationship, Radiation; Humans; Mice; Models, Biological; Neoplasms, Radiation-Induced; Plutonium; Radiation Dosage; Radium; Rats; Risk Assessment; Risk Factors; Species Specificity | 2006 |
Osteochondromas and growth retardation secondary to externally or internally administered radiation in childhood.
Topics: Bone and Bones; Bone Development; Bone Marrow Transplantation; Bone Neoplasms; Child; Growth Disorders; Humans; Infant; Neoplasms; Osteochondroma; Radiation Dosage; Radiopharmaceuticals; Radiotherapy; Radium; Thorium; Transplantation Conditioning; Tuberculosis, Osteoarticular; Whole-Body Irradiation | 2007 |
Radium-223 for men with hormone-refractory prostate cancer and bone metastases.
Topics: Alkaline Phosphatase; Bone Neoplasms; Drug Resistance, Neoplasm; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radium | 2007 |
Determination of 226Ra in cheese produced in the rural area of Pernambuco-Brazil.
Topics: Bone Neoplasms; Brazil; Carcinoma; Cheese; Environmental Monitoring; Epidemiological Monitoring; Food Contamination, Radioactive; Radioactive Pollutants; Radium; Risk Assessment; Sarcoma; Skull Neoplasms | 2007 |
The risk of bone cancer in man from internally deposited radium.
Topics: Bone Neoplasms; Environmental Exposure; Humans; Occupational Diseases; Radium | 1967 |
Comparison of the carcinogenicity of radium and bone-seeking actinides.
Topics: Actinoid Series Elements; Alpha Particles; Animals; Bone and Bones; Bone Neoplasms; Dogs; Models, Biological; Neoplasms, Radiation-Induced; Osteosarcoma; Radium; Relative Biological Effectiveness; Risk; Time Factors | 1984 |
The role of time-factor and RBE for the induction of osteosarcomas by incorporated short-lived bone-seekers.
Topics: Animals; Bone Neoplasms; Lutetium; Male; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Osteosarcoma; Radioisotopes; Radium; Relative Biological Effectiveness; Strontium Radioisotopes; Thorium; Time Factors | 1983 |
Sites of incidence of osteosarcoma in the long bones of man and the beagle.
Topics: Alpha Particles; Animals; Bone and Bones; Bone Neoplasms; Dogs; Dose-Response Relationship, Radiation; Humans; Male; Middle Aged; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Osteosarcoma; Plutonium; Radium; Thorium | 1983 |
[Theoretical evaluation of the expected yield of osteosarcomas after radium isotope intake].
Topics: Animals; Bone Neoplasms; Dose-Response Relationship, Radiation; Mathematics; Models, Biological; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Osteosarcoma; Radium; Risk | 1983 |
226Ra induced bone-cancers: the effects of a delayed Na-alginate treatment.
Topics: Alginates; Animals; Bone Neoplasms; Decontamination; Male; Mice; Mice, Inbred C57BL; Neoplasms, Radiation-Induced; Osteosarcoma; Radium; Time Factors; Tissue Distribution | 1983 |
Comparative toxicity of 226Ra, 239Pu, 241Am, 249Cf, and 252Cf in C57BL/Do black and albino mice.
Topics: Alpha Particles; Americium; Animals; Bone Neoplasms; Californium; Dose-Response Relationship, Radiation; Female; Injections, Intravenous; Male; Mice; Mice, Inbred C57BL; Models, Biological; Neoplasms, Radiation-Induced; Plutonium; Radioactivity; Radium; Risk; Sarcoma, Experimental; Sex Factors | 1983 |
Radium retention in mature beagles injected at 5 years of age.
Topics: Age Factors; Animals; Body Burden; Bone and Bones; Bone Neoplasms; Dogs; Feces; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Radium; Radon; Spectrometry, Gamma; Time Factors | 1983 |
Chronic radium intoxication: radium osteonecrosis and cancer in relation to 226Ra burdens.
Topics: Background Radiation; Body Burden; Bone Neoplasms; Chronic Disease; Femur; Humans; Neoplasms, Radiation-Induced; New Jersey; Occupational Diseases; Osteoradionecrosis; Radiation Injuries; Radium | 1983 |
Cells at risk for the production of bone tumors in radium exposed individuals: an electron microscope study.
Topics: Aged; Bone Marrow; Bone Neoplasms; Cell Nucleus; Female; Femoral Neoplasms; Femur; Humans; Male; Microscopy, Electron; Neoplasms, Radiation-Induced; Occupational Diseases; Radium; Risk | 1983 |
Dose-response relationships for radium-induced bone sarcomas.
Topics: Adult; Age Factors; Bone Neoplasms; Dose-Response Relationship, Radiation; Female; Humans; Male; Middle Aged; Neoplasms, Radiation-Induced; Occupational Diseases; Radium; Risk; Sarcoma; Sex Factors; Time Factors; United States | 1983 |
Follow-up study of late effects in 224Ra treated ankylosing spondylitis patients.
Topics: Aged; Bone Neoplasms; Cataract; Female; Follow-Up Studies; Germany, West; Humans; Male; Middle Aged; Neoplasms, Radiation-Induced; Radiotherapy Dosage; Radium; Risk; Spondylitis, Ankylosing | 1983 |
Lifetime bone cancer dose-response relationships in beagles and people from skeletal burdens of 226Ra and 90Sr.
Topics: Animals; Body Burden; Bone Neoplasms; Dogs; Dose-Response Relationship, Radiation; Humans; Life Expectancy; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Radium; Relative Biological Effectiveness; Risk; Strontium Radioisotopes | 1983 |
Comparison of radiological changes in humans and beagles with skeletal deposits of radium.
Topics: Animals; Bone and Bones; Bone Neoplasms; Dogs; Humans; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Occupational Diseases; Osteoradionecrosis; Radiation Injuries, Experimental; Radiography; Radium; Sarcoma | 1983 |
Plutonium-induced osteosarcomas in the St. Bernard.
Topics: Animals; Body Weight; Bone Neoplasms; Dogs; Dose-Response Relationship, Radiation; Neoplasms, Radiation-Induced; Osteosarcoma; Plutonium; Radiation Tolerance; Radium; Time Factors | 1981 |
Lifetime studies of 226Ra and 90Sr toxicity in beagles--a status report.
Topics: Animals; Body Burden; Bone Marrow Diseases; Bone Neoplasms; Dogs; Dose-Response Relationship, Radiation; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Radiation Injuries, Experimental; Radium; Soft Tissue Neoplasms; Strontium Radioisotopes; Time Factors; Toxicology | 1981 |
Dose-response relationships for bone tumors in beagles exposed to 226Ra and 90Sr.
Topics: Animals; Bone Neoplasms; Diet; Dogs; Dose-Response Relationship, Radiation; Female; Humans; Injections, Intravenous; Mice; Neoplasms, Radiation-Induced; Radium; Strontium Radioisotopes | 1981 |
Bone cancer from radium: canine dose response explains data for mice and humans.
Topics: Animals; Bone Neoplasms; Disease Models, Animal; Dogs; Dose-Response Relationship, Radiation; Humans; Mice; Neoplasms, Radiation-Induced; Radium; Species Specificity | 1980 |
Radium in drinking water and the risk of death from bone cancer among Ontario youths.
Topics: Adolescent; Adult; Background Radiation; Bone Neoplasms; Child; Environmental Exposure; Female; Humans; Male; Neoplasms, Radiation-Induced; Ontario; Radium; Regression Analysis; Risk Factors; Water Supply | 1994 |
Relative effectiveness of 239Pu and some other internal emitters for bone cancer induction in beagles.
Topics: Animals; Bone Neoplasms; Dogs; Female; Male; Neoplasms, Radiation-Induced; Plutonium; Radium | 1994 |
Bone sarcoma characteristics and distribution in beagles injected with radium-226.
Topics: Animals; Bone Neoplasms; Cohort Studies; Dogs; Dose-Response Relationship, Radiation; Female; Incidence; Male; Neoplasms, Multiple Primary; Neoplasms, Radiation-Induced; Osteosarcoma; Radium | 1994 |
Comparing bone sarcoma induction in humans from 224Ra and 226+228Ra.
Topics: Bone Neoplasms; Humans; Neoplasms, Radiation-Induced; Radium; Sarcoma; Thorium | 1993 |
Radium in drinking water and risk of bone cancer in Ontario youths: a second study and combined analysis.
Topics: Adolescent; Adult; Bone Neoplasms; Case-Control Studies; Child; Dose-Response Relationship, Radiation; Environmental Exposure; Female; Humans; Male; Models, Biological; Neoplasms, Radiation-Induced; Odds Ratio; Ontario; Osteosarcoma; Radium; Water Pollution, Radioactive | 1996 |
The biological effects of radium-224 injected into dogs.
Topics: Animals; Bone Neoplasms; Cataract; Dogs; Female; Kidney Neoplasms; Liver Neoplasms, Experimental; Male; Mammary Neoplasms, Experimental; Neoplasms, Radiation-Induced; Nose Neoplasms; Radiation Dosage; Radium | 1996 |
Radium dial workers: issues concerning dose response and modeling.
Topics: Bone Neoplasms; Dose-Response Relationship, Radiation; Female; Head and Neck Neoplasms; Humans; Models, Biological; Neoplasms, Radiation-Induced; Occupational Exposure; Radium; Sarcoma | 1997 |
Relationship of natural incidence and radiosensitivity for bone cancer in dogs.
Topics: Animals; Bone Neoplasms; Dog Diseases; Dogs; Incidence; Neoplasms, Radiation-Induced; Plutonium; Radiation Tolerance; Radium; Risk Factors; Sarcoma; Species Specificity | 1997 |
Bone tumor location in dogs given skeletal irradiation by 239Pu or 226Ra.
Topics: Aging; Americium; Animals; Bone Neoplasms; Californium; Dogs; Neoplasms, Radiation-Induced; Organ Specificity; Plutonium; Radium; Thorium | 1997 |
Does age of the host affect growth rates of skeletal malignancies?
Topics: Age Factors; Animals; Bone Neoplasms; Dogs; Dose-Response Relationship, Radiation; Lead Radioisotopes; Neoplasms, Radiation-Induced; Probability; Radium; Spinal Neoplasms | 1998 |
Studies of U.S. radium dial workers: an epidemiological classic.
Topics: Anemia; Bone Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Lymphoid Tissue; Neoplasms, Radiation-Induced; Occupational Exposure; Osteitis; Osteosarcoma; Radium; United States | 1998 |
Relative radiosensitivity of bone tumor induction among beagles as a function of age at injection of 239Pu or 226Ra.
Topics: Age Factors; Animals; Bone Neoplasms; Dogs; Dose-Response Relationship, Radiation; Neoplasms, Radiation-Induced; Plutonium; Radium | 1999 |
Some problems in the skeletal dosimetry of bone-seeking radionuclides.
Topics: Age Factors; Animals; Bone and Bones; Bone Neoplasms; Dogs; Dose-Response Relationship, Radiation; Humans; Mice; Microspheres; Models, Biological; Plutonium; Radioisotopes; Radiometry; Radium; Strontium Radioisotopes; Yttrium Radioisotopes | 1999 |
Malignancies in patients treated with high doses of radium-224.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Breast Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Kidney Neoplasms; Leukemia, Radiation-Induced; Male; Middle Aged; Neoplasms, Radiation-Induced; Radium; Sarcoma; Spondylitis, Ankylosing; Urinary Bladder Neoplasms | 1999 |
Late effects in ankylosing spondylitis patients treated with 224Ra.
Topics: Adult; Aged; Bone Neoplasms; Female; Follow-Up Studies; Humans; Leukemia, Radiation-Induced; Male; Middle Aged; Neoplasms, Radiation-Induced; Radium; Spondylitis, Ankylosing | 1999 |
Induction of malignant bone tumors in radium-224 patients: risk estimates based on the improved dosimetry.
Topics: Adolescent; Adult; Age Distribution; Age Factors; Bone Neoplasms; Child; Chordoma; Cohort Studies; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Germany; Humans; Incidence; Likelihood Functions; Lymphoma; Male; Neoplasms, Radiation-Induced; Radiometry; Radium; Risk Assessment; Sarcoma; Sex Distribution; Thorium | 2000 |
An analysis of bone and head sinus cancers in radium dial painters using a two-mutation carcinogenesis model.
Topics: Adult; Bone Neoplasms; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Humans; Neoplasms, Radiation-Induced; Occupational Diseases; Paranasal Sinus Neoplasms; Radiation Dosage; Radium | 2000 |
Does body size contribute to sensitivity of bone tumor induction by radionuclide exposure?
Topics: Animals; Body Constitution; Bone Neoplasms; Dogs; Dose-Response Relationship, Radiation; Neoplasms, Radiation-Induced; Plutonium; Radiation Dosage; Radioisotopes; Radium; Regression Analysis; Sensitivity and Specificity; Strontium Radioisotopes; Thorium; Time | 2000 |
Effective thresholds for induction of skeletal malignancies by radionuclides.
Topics: Americium; Animals; Bone Neoplasms; Dogs; Neoplasms, Radiation-Induced; Plutonium; Radium; Strontium Radioisotopes; Thorium | 2000 |
Bone cancer risk.
Topics: Bone Neoplasms; Environmental Exposure; Humans; Neoplasms, Radiation-Induced; Occupational Diseases; Radium; Risk Factors; Strontium | 2001 |
Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.
Topics: Alpha Particles; Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Humans; Mice; Mice, Inbred BALB C; Radium; Rats; Rats, Nude; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Late effects after incorporation of the short-lived alpha-emitters 224Ra and 227Th in mice.
Topics: Animals; Bone Neoplasms; Dose-Response Relationship, Radiation; Female; Fibroma; Leukemia, Radiation-Induced; Lung Neoplasms; Male; Mice; Neoplasms, Experimental; Neoplasms, Multiple Primary; Neoplasms, Radiation-Induced; Ossification, Heterotopic; Osteosarcoma; Radium; Sex Factors; Thorium; Time Factors | 1978 |
Aspects of the dosimetry of alpha-emitting radionuclides in bone with particular emphasis on 226Ra and 239Pu.
Topics: Animals; Bone and Bones; Bone Marrow; Bone Marrow Cells; Bone Neoplasms; Humans; Leukemia; Mathematics; Neoplasms, Radiation-Induced; Osteosarcoma; Plutonium; Radiation Monitoring; Radium | 1977 |
The osteosarcomogenic effectiveness of the short-lived 224Ra compared with that of the long-lived 226Ra in mice.
Topics: Animals; Bone Neoplasms; Dose-Response Relationship, Radiation; Female; Half-Life; Mice; Neoplasms, Radiation-Induced; Osteosarcoma; Radium | 1977 |
Planimetric evaluation and comparison of roentgenograms of osteogenic sarcomas induced by 226Ra and 224Ra in mice.
Topics: Animals; Bone Neoplasms; Female; Injections; Mice; Neoplasms, Radiation-Induced; Osteosarcoma; Radiography; Radium; Sarcoma, Experimental | 1977 |
3H-TDR labelling of osteoprogenitor cells after 226RA incorporation in mice.
Topics: Animals; Autoradiography; Bone and Bones; Bone Neoplasms; Cell Division; DNA; Dose-Response Relationship, Radiation; Female; Mice; Neoplasms, Radiation-Induced; Osteosarcoma; Radium; Thymidine; Tritium | 1977 |
Measurements of endosteal surface areas in human long bones: relationship to sites of occurrence of osteosarcoma.
Topics: Anthropometry; Bone and Bones; Bone Neoplasms; Humans; Neoplasms, Radiation-Induced; Osteosarcoma; Radionuclide Imaging; Radiotherapy; Radiotherapy Dosage; Radium | 1977 |
Skeletal effects following 224Ra injections into humans.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Exostoses; Female; Growth; Growth Disorders; Humans; Male; Middle Aged; Neoplasms, Radiation-Induced; Osteosarcoma; Radium; Sarcoma; Tooth; Tooth Fractures | 1978 |
The radiobiological significance of the studies with 224Ra and thorotrast.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Neoplasms; Hemangioendothelioma; Humans; Leukemia, Radiation-Induced; Liver Neoplasms; Lung Neoplasms; Multiple Myeloma; Neoplasms, Radiation-Induced; Osteosarcoma; Radium; Thorium Dioxide | 1978 |
Dose-response relationships for female radium dial workers.
Topics: Age Factors; Bone Neoplasms; Dose-Response Relationship, Radiation; Female; Head and Neck Neoplasms; Humans; Neoplasms, Radiation-Induced; Occupational Diseases; Osteosarcoma; Radium; Radon; Registries; Retrospective Studies; Time Factors | 1978 |
Competitive radiation-induced carcinogenesis: an analysis of data from beagle dogs exposed to 226Ra and 90Sr.
Topics: Age Factors; Animals; Bone Neoplasms; Diet; Dogs; Dose-Response Relationship, Radiation; Female; Injections, Intravenous; Male; Myeloproliferative Disorders; Neoplasms, Radiation-Induced; Osteosarcoma; Radium; Respiration; Strontium Radioisotopes; Yttrium Radioisotopes | 1979 |
Osteosarcoma induced by short-lived bone-seeking alpha emitters in mice: the role of age.
Topics: Age Factors; Alpha Particles; Animals; Bone Neoplasms; Female; Injections, Intraperitoneal; Mice; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Osteosarcoma; Radium; Thorium | 1979 |
The New Jersey radium dial painters: a classic in occupational carcinogenesis.
Topics: Adult; Anemia, Aplastic; Bone Neoplasms; Female; History, 20th Century; Humans; Jaw Diseases; Male; Neoplasms, Radiation-Induced; New Jersey; Occupational Diseases; Osteonecrosis; Osteoradionecrosis; Paint; Radium | 1978 |
Bone tumors in thorotrast patients.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Denmark; Dose-Response Relationship, Radiation; Female; Germany; Humans; Male; Middle Aged; Neoplasms, Radiation-Induced; Plutonium; Portugal; Radium; Risk; Sarcoma; Thorium Dioxide | 1979 |
Exostoses induced by 224Ra (ThX) in children.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Exostoses; Female; Humans; Infant; Male; Neoplasms, Radiation-Induced; Radium; Sarcoma; Sex Factors | 1979 |
Bone cancer among female radium dial workers. Latency periods and incidence rates by time after exposure: brief communication.
Topics: Adolescent; Adult; Age Factors; Aged; Bone Neoplasms; Dose-Response Relationship, Radiation; Female; Humans; Middle Aged; Neoplasms, Radiation-Induced; Occupational Diseases; Radiation Dosage; Radium; Time Factors; United States | 1978 |
[Animal experimental studies with radium 224].
Topics: Alkaline Phosphatase; Animals; Bone Neoplasms; Dose-Response Relationship, Radiation; Female; Mice; Neoplasms, Radiation-Induced; Radium; Risk; Thorium | 1978 |
Current status of the study of 226Ra and 228Ra in humans at the center for human radiobiology.
Topics: Bone Neoplasms; Carcinoma; Humans; Mastoid; Neoplasms, Radiation-Induced; Occupational Diseases; Paranasal Sinus Neoplasms; Radium; Sarcoma; Skull Neoplasms | 1978 |
A theory of the induction of bone cancer by alpha radiation.
Topics: Alpha Particles; Animals; Bone Neoplasms; Cell Survival; Dogs; Dose-Response Relationship, Radiation; Humans; Mathematics; Methods; Models, Biological; Neoplasms, Radiation-Induced; Probability; Radium; Species Specificity; Statistics as Topic; Time Factors | 1977 |
Radiographic features of bone in several strains of laboratory mice and of their tumours induced by bone-seeking radionuclides.
Topics: Aging; Animals; Bone and Bones; Bone Neoplasms; Fibrosarcoma; Hemangiosarcoma; Lymphoma; Mice; Mice, Inbred A; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Inbred Strains; Neoplasms, Radiation-Induced; Osteosarcoma; Plutonium; Radiography; Radium; Species Specificity; Strontium Radioisotopes | 1976 |
Experimental induction of bone tumors by short-lived bone-seeking radionuclides.
Topics: Animals; Bone Diseases, Developmental; Bone Neoplasms; Dose-Response Relationship, Radiation; Female; Half-Life; Male; Mice; Neoplasms, Experimental; Neoplasms, Multiple Primary; Neoplasms, Radiation-Induced; Osteosarcoma; Radium; Skull Neoplasms; Spinal Neoplasms; Thorium; Time Factors | 1976 |
Viruses in osteosarcomas induced by 226Ra. A study of the induction of bone tumours in mice.
Topics: Animals; Bone Neoplasms; Female; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred CBA; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Oncogenic Viruses; Osteosarcoma; Radium; Virus Replication | 1975 |
Interspecies scaling of risk for radiation-induced bone cancer.
Topics: Animals; Bone Neoplasms; Dogs; Humans; Mice; Neoplasms, Radiation-Induced; Radium; Risk; Species Specificity | 1990 |
Dose and dose-rate dependence for bone sarcomas in radium-224 patients.
Topics: Bone Neoplasms; Dose-Response Relationship, Radiation; Humans; Neoplasms, Radiation-Induced; Osteosarcoma; Radiation Dosage; Radium; Spondylitis, Ankylosing | 1990 |
Distribution of radium-induced bone cancers in beagles and comparison with humans.
Topics: Animals; Body Burden; Bone and Bones; Bone Neoplasms; Dogs; Humans; Injections, Intravenous; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Radium | 1991 |
The influence of age at time of exposure to 226Ra or 239Pu on distribution, retention, postinjection survival, and tumor induction in beagle dogs.
Topics: Aging; Animals; Bone and Bones; Bone Neoplasms; Dogs; Injections, Intravenous; Neoplasms, Radiation-Induced; Plutonium; Radiation Injuries, Experimental; Radium | 1991 |
Toxicity of 241Am in male C57BL mice: relative risk versus 226Ra.
Topics: Americium; Animals; Bone Neoplasms; Injections, Intraperitoneal; Life Expectancy; Male; Mice; Mice, Inbred C57BL; Neoplasms, Radiation-Induced; Radium; Risk | 1991 |
The reverse protraction factor in the induction of bone sarcomas in radium-224 patients.
Topics: Adolescent; Adult; Bone Neoplasms; Female; Follow-Up Studies; Germany, West; Humans; Injections, Intravenous; Male; Neoplasms, Radiation-Induced; Osteosarcoma; Proportional Hazards Models; Radium; Spondylitis, Ankylosing; Time Factors; Tuberculosis, Osteoarticular | 1990 |
Induction of lymphoma and osteosarcoma in mice by single and protracted low alpha doses.
Topics: Alpha Particles; Animals; Bone Neoplasms; Female; Injections, Intraperitoneal; Lymphoma; Mice; Neoplasms, Radiation-Induced; Osteosarcoma; Radiation Dosage; Radium | 1990 |
Scaling of fatal cancer risks from laboratory animals to man.
Topics: Animals; Bone Neoplasms; Diethylnitrosamine; Dogs; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Mice; Neoplasms; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Plutonium; Radium; Rats; Risk; Species Specificity | 1989 |
Endogenous murine leukemia viruses: frequency of radiation-activation and novel pathogenic effects of viral isolates.
Topics: Animals; Antibodies, Viral; Antigens, Viral; Bone Neoplasms; Dose-Response Relationship, Radiation; Female; Lymphoma; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Osteoma; Osteopetrosis; Radium; Retroviridae; Virus Activation | 1988 |
Pathology of radiation-induced bone tumors.
Topics: Animals; Bone Neoplasms; Humans; Mice; Neoplasm Metastasis; Neoplasms, Radiation-Induced; Occupational Diseases; Osteosarcoma; Radium; Sarcoma; Time Factors | 1986 |
The prediction of the relative toxicities of radium 224 and of radium 226 in the bones of mice using Monte Carlo techniques.
Topics: Animals; Biometry; Bone and Bones; Bone Marrow; Bone Neoplasms; Mice; Monte Carlo Method; Neoplasms, Radiation-Induced; Osteosarcoma; Radiation Dosage; Radium | 1987 |
Cancer incidence and lifespan vs. alpha-particle dose in beagles.
Topics: Alpha Particles; Americium; Animals; Bone Neoplasms; Dogs; Dose-Response Relationship, Radiation; Longevity; Plutonium; Radium; Sarcoma, Experimental; Thorium | 1987 |
Late effects of 226Ra, 224Ra and 239Pu in female mice of the ICR strain.
Topics: Animals; Bone Neoplasms; Dose-Response Relationship, Radiation; Female; Mice; Mice, Inbred ICR; Neoplasms, Radiation-Induced; Osteosarcoma; Plutonium; Radium; Risk; Time Factors | 1985 |
Cancer risk from the lifetime intake of Ra and U isotopes.
Topics: Alpha Particles; Bone Neoplasms; Cost-Benefit Analysis; Dose-Response Relationship, Radiation; Half-Life; Head and Neck Neoplasms; Humans; Leukemia, Radiation-Induced; Life Expectancy; Mathematics; Neoplasms, Radiation-Induced; Occupational Diseases; Radiation Dosage; Radium; Risk; Sarcoma; Soft Tissue Neoplasms; Uranium; Water Pollutants, Radioactive; Water Supply | 1985 |
Metabolism of ingested U and Ra.
Topics: Animals; Body Burden; Bone and Bones; Bone Neoplasms; Calcium; Humans; Intestinal Absorption; Kidney; Maximum Allowable Concentration; Models, Biological; Neoplasms, Radiation-Induced; Radiation Dosage; Radiation Injuries; Radium; Risk; Sarcoma; Uranium; Water Pollutants, Radioactive; Water Supply | 1985 |
243,244Cm studies in C57BL/Do mice.
Topics: Animals; Bone and Bones; Bone Neoplasms; Curium; Female; Kinetics; Male; Mathematics; Mice; Mice, Inbred C57BL; Neoplasms, Radiation-Induced; Radium; Relative Biological Effectiveness; Sarcoma, Experimental | 1985 |
Current (1984) status of the study of 226Ra and 228Ra in humans at the Center for Human Radiobiology.
Topics: Bone Neoplasms; Follow-Up Studies; Head and Neck Neoplasms; Humans; Neoplasms, Radiation-Induced; Occupational Diseases; Population Surveillance; Radiation Dosage; Radium; United States | 1985 |
Bone sarcoma cumulative tumor rates in patients injected with 224Ra.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Child; Female; Follow-Up Studies; Germany, West; Humans; Male; Neoplasms, Radiation-Induced; Radium; Sarcoma; Spondylitis, Ankylosing; Thorium; Time Factors; Tuberculosis | 1985 |
A proportional hazards analysis of bone sarcoma rates in German 224radium patients.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Female; Follow-Up Studies; Germany, West; Humans; Male; Neoplasms, Radiation-Induced; Radiation Dosage; Radium; Sarcoma; Thorium | 1985 |
224Ra: risk to bone and haematopoietic tissue in ankylosing spondylitis patients.
Topics: Bone Neoplasms; Female; Follow-Up Studies; Germany, West; Humans; Leukemia, Radiation-Induced; Male; Neoplasms, Radiation-Induced; Radiation Dosage; Radium; Risk; Spondylitis, Ankylosing; Thorium; Time Factors | 1985 |
Relationship of bone composition to the location of radium-induced bone cancer.
Topics: Animals; Bone and Bones; Bone Neoplasms; Dogs; Female; Neoplasms, Radiation-Induced; Radiation Dosage; Radium; Sarcoma, Experimental | 1985 |
The osteosarcomogenic efficiency of low 224radium-doses in mice compared to that of the short-lived beta-emitting rare earth 177lutetium.
Topics: Animals; Bone Neoplasms; Dose-Response Relationship, Radiation; Female; Lutetium; Mice; Neoplasms, Radiation-Induced; Radioisotopes; Radium; Sarcoma, Experimental; Thorium | 1985 |
[Disturbance of bone growth after incorporation of 224Ra (thorium X) in mice (author's transl)].
Topics: Animals; Bone Development; Bone Neoplasms; Mice; Mice, Inbred Strains; Neoplasms, Radiation-Induced; Radiation Injuries, Experimental; Radium; Sarcoma, Experimental; Thorium | 1972 |
[Radiation pathology of the skeletal system].
Topics: Animals; Bone and Bones; Bone Neoplasms; Humans; Neoplasms, Radiation-Induced; Osteoradionecrosis; Radiation Injuries, Experimental; Radium | 1972 |
[Late lesions following incorporation of 224Ra in animal experiment].
Topics: Animals; Bone Neoplasms; Female; Germany, West; Male; Mice; Mice, Inbred Strains; Neoplasms, Radiation-Induced; Osteosarcoma; Radioisotope Teletherapy; Radiotherapy Dosage; Radium; Sarcoma, Experimental; Sex Factors; Thorium; Time Factors | 1972 |
Radionuclides and bone--from 226Ra to 90Sr.
Topics: Adult; Air Pollution, Radioactive; Animals; Bone Marrow; Bone Marrow Cells; Bone Neoplasms; Dogs; Dose-Response Relationship, Drug; Energy Transfer; Humans; Infant; Male; Maximum Allowable Concentration; Neoplasms, Radiation-Induced; Radiation Dosage; Radiation Effects; Radiation Protection; Radiobiology; Radionuclide Imaging; Radiotherapy Dosage; Radium; Strontium Radioisotopes | 1974 |
[Current indications for and use of high energy ionizing radiations].
Topics: Bone Neoplasms; Breast Neoplasms; Cesium; Cobalt Radioisotopes; Female; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Humans; Iridium; Lymphoma; Mouth Neoplasms; Neoplasm Metastasis; Neoplasms; Radiobiology; Radioisotope Teletherapy; Radium; Respiratory Tract Neoplasms; Skin Neoplasms; Spinal Cord Neoplasms; Urogenital Neoplasms | 1974 |
Radiation dose-time relations for induction of osteosarcoma in mice and dogs and their bearing on maximal permissible burden of 90 Sr in man.
Topics: Animals; Body Burden; Bone Neoplasms; Dogs; Dose-Response Relationship, Radiation; Environmental Exposure; Female; Humans; Maximum Allowable Concentration; Mice; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Osteosarcoma; Plutonium; Radium; Rats; Strontium Isotopes | 1972 |
[Elapsed time for the appearance of skeletal neoplasms in animals and man due to radioactive isotopes].
Topics: Animals; Bone Neoplasms; Cerium Isotopes; Dogs; Humans; Mice; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Osteosarcoma; Plutonium; Radioisotopes; Radium; Rats; Strontium Isotopes; Thorium; Time Factors | 1973 |
Virus-like particles in 224Ra-induced murine osteosarcomas.
Topics: Animals; Bone Neoplasms; Endoplasmic Reticulum; Female; Liver Neoplasms; Mice; Microscopy, Electron; Neoplasm Metastasis; Neoplasms, Radiation-Induced; Osteosarcoma; Radium; Sarcoma, Experimental; Viruses | 1974 |
Morphological evaluation of 226Ra induced osteogenic sarcoma in mice;.
Topics: Animals; Bone Neoplasms; Female; Mandibular Neoplasms; Mice; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Osteosarcoma; Radium; Skull Neoplasms; Spinal Neoplasms | 1974 |
The skeletal dose from 224Ra following intravascular administration of thorotrast.
Topics: Body Burden; Bone and Bones; Bone Neoplasms; Colloids; Dose-Response Relationship, Radiation; Female; Humans; Liver; Male; Neoplasms, Radiation-Induced; Organ Specificity; Radiation Dosage; Radiation Effects; Radium; Sarcoma; Spleen; Thorium Dioxide | 1973 |
[10-year statistics of cobalt 60 radiotherapy for carcinoma in private practice].
Topics: Adult; Age Factors; Aged; Bone Neoplasms; Breast Neoplasms; Bronchial Neoplasms; Cobalt Isotopes; Esophageal Neoplasms; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Kidney Neoplasms; Male; Middle Aged; Mouth Neoplasms; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Radioisotope Teletherapy; Radiotherapy Dosage; Radiotherapy, High-Energy; Radium; Skin Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms | 1972 |
[Radiation pathology (demonstration)].
Topics: Alpha Particles; Animals; Bone Neoplasms; Female; Mice; Neoplasms, Radiation-Induced; Radioisotopes; Radium; Sarcoma, Experimental; Thorium | 1973 |
Complications of radiation therapy: adult bone.
Topics: Adult; Bone and Bones; Bone Diseases; Bone Neoplasms; Femur Head Necrosis; Femur Neck; Humans; Mandibular Diseases; Necrosis; Osteitis; Pelvic Bones; Radiation Dosage; Radiation Injuries; Radiography; Radiotherapy; Radium; Sarcoma | 1974 |
Bone cancers induced by 224 Ra (Th X) in children and adults.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Child; Child, Preschool; Chondrosarcoma; Female; Fibrosarcoma; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Radiation-Induced; Osteosarcoma; Radiometry; Radium; Retrospective Studies; Sarcoma; Spondylitis, Ankylosing; Tuberculosis, Lymph Node; Tuberculosis, Osteoarticular; Tuberculosis, Pulmonary | 1970 |
An epidemiologic approach to low-level radium 226 exposure.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Child; Child, Preschool; Female; Humans; Illinois; Infant; Infant, Newborn; Iowa; Male; Middle Aged; Neoplasms; Radium; Retrospective Studies; Water Pollution, Radioactive | 1966 |
Radiation therapy of skin carcinoma.
Topics: Aged; Bone Neoplasms; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cobalt Isotopes; Ear Neoplasms; Eye Neoplasms; Facial Neoplasms; Female; Hand; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mouth Neoplasms; Neoplasm Metastasis; Radiotherapy, High-Energy; Radium; Skin Neoplasms; Skull Neoplasms | 1971 |
The radium standard for boneseekers--evaluation of the data on radium patients and dial painters.
Topics: Accidents, Occupational; Bone Neoplasms; Environmental Exposure; Fractures, Spontaneous; Humans; Mastoid; Neoplasms, Radiation-Induced; Nose Neoplasms; Occupational Diseases; Osteomyelitis; Osteoporosis; Osteosarcoma; Paint; Radiation Injuries; Radiation Protection; Radiometry; Radium | 1967 |
Radiation dose-time relations for induction of bone tumors in the dog and skin tumors in the rat.
Topics: Animals; Bone Neoplasms; Dogs; Female; Injections; Male; Neoplasms, Experimental; Osteosarcoma; Plutonium; Radium; Rats; Skin Neoplasms; Thorium; Time Factors | 1968 |
Bone-seeking radionuclides.
Topics: Animals; Bone and Bones; Bone Neoplasms; Dogs; Humans; Idaho; Neoplasms, Radiation-Induced; Osteosarcoma; Plutonium; Radiobiology; Radium; Skull Neoplasms; Strontium Isotopes | 1968 |
Malignancy from radium.
Topics: Aged; Bone Marrow; Bone Neoplasms; Female; Humans; Leukemia, Radiation-Induced; Male; Neoplasms, Radiation-Induced; Occupational Diseases; Osteosarcoma; Radiometry; Radiotherapy; Radium | 1970 |
Speculated risk to bone and liver from 239 Pu.
Topics: Adult; Animals; Body Burden; Bone Neoplasms; Child; Dogs; Female; Humans; Life Expectancy; Liver Neoplasms; Male; Maximum Allowable Concentration; Models, Biological; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Occupational Diseases; Osteosarcoma; Plutonium; Radiobiology; Radiometry; Radium; Species Specificity; Thorium | 1970 |
Radium osteitis with osteogenic sarcoma: the chronology and natural history of a fatal case.
Topics: Adult; Bone Neoplasms; Female; Humans; Neoplasms, Radiation-Induced; Occupational Diseases; Osteitis; Osteosarcoma; Radiation Injuries; Radium | 1971 |
The question of safe radiation thresholds for alpha emitting bone seekers in man.
Topics: Alpha Particles; Bone and Bones; Bone Neoplasms; Environmental Exposure; Humans; Models, Biological; Neoplasms, Radiation-Induced; Osteosarcoma; Radiation Protection; Radiobiology; Radium; Time Factors | 1971 |
Methods of assay of the relative toxicity of certain bone-seeking radionuclides.
Topics: Animals; Bone and Bones; Bone Neoplasms; Dogs; Injections, Intravenous; Mathematics; Methods; Models, Biological; Neoplasms, Radiation-Induced; Osteosarcoma; Plutonium; Radiation Dosage; Radiometry; Radium; Statistics as Topic; Strontium Isotopes; Thorium | 1971 |
[Radiation carcinogenesis. Pathogenesis of radiation-induced neoplasms].
Topics: Bone Neoplasms; Chondroma; Chondrosarcoma; Fibroma; Humans; Neoplasms, Radiation-Induced; Osteoma, Osteoid; Osteosarcoma; Radium | 1970 |
Radiation-induced sarcoma of bone.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Child; Child, Preschool; Female; Humans; Infant; Male; Middle Aged; Neoplasms, Radiation-Induced; Occupational Diseases; Osteosarcoma; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Radium; Retrospective Studies; Uterine Cervical Neoplasms | 1971 |
[Late damages after 224Ra injections in men].
Topics: Adolescent; Adult; Age Factors; Bone Neoplasms; Child; Child, Preschool; Chondrosarcoma; Chromosomes; Congenital Abnormalities; Female; Fibroma; Fingers; Humans; Infant; Male; Osteosarcoma; Radiation Dosage; Radiation Effects; Radium; Sex Factors; Time Factors; Tuberculosis, Osteoarticular; Tuberculosis, Pulmonary | 1970 |
Roentgenographic analysis of 226 Ra induced osteogenic sarcoma in mice.
Topics: Adenocarcinoma; Animals; Bone Neoplasms; Mice; Neoplasms, Radiation-Induced; Osteosarcoma; Radiography; Radium; Sarcoma, Experimental | 1971 |
Radium-induced malignant tumors in man. ANL-7461.
Topics: Bone Neoplasms; Chicago; Female; Follow-Up Studies; Humans; Iatrogenic Disease; Leukemia; Male; Neoplasms, Radiation-Induced; Occupational Diseases; Radium | 1968 |
Studies on short-lived internal -emitters in mice and rats. II. 227 Th.
Topics: Alpha Particles; Animals; Autoradiography; Bone and Bones; Bone Neoplasms; Feces; Half-Life; Mice; Neoplasms, Radiation-Induced; Radiation Dosage; Radiation Effects; Radium; Rats; Sarcoma; Thorium | 1971 |
[Short-term effect of radiation on rectal and gastric mucosa: presentation of 2 cases].
Topics: Adenocarcinoma; Adult; Bone Neoplasms; Endometriosis; Female; Gastric Mucosa; Humans; Intestinal Mucosa; Male; Middle Aged; Neoplasm Metastasis; Peptic Ulcer; Radiation Effects; Radium; Rectum; Time Factors; Uterine Neoplasms | 1969 |
Application of 18F to image 226Ra-induced bone lesions.
Topics: Animals; Bone and Bones; Bone Diseases; Bone Neoplasms; Dogs; Fluorine; Radiography; Radioisotopes; Radionuclide Imaging; Radium; Regional Blood Flow | 1970 |
The malignant tumour risk from radium body burdens.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Body Burden; Bone Neoplasms; Brain Neoplasms; Environmental Health; Female; Follow-Up Studies; Humans; Leukemia, Radiation-Induced; Male; Maximum Allowable Concentration; Methods; Middle Aged; Models, Biological; Neoplasms, Radiation-Induced; Paranasal Sinus Neoplasms; Radiation Protection; Radium; Skull Neoplasms; Spinal Cord Neoplasms | 1970 |
[Cervix carcinoma in multiple primary neoplasms].
Topics: Adenocarcinoma; Adult; Aged; Bone Neoplasms; Bronchial Neoplasms; Colonic Neoplasms; Female; Gallbladder Neoplasms; Humans; Leiomyosarcoma; Middle Aged; Neoplasms, Multiple Primary; Ovarian Neoplasms; Radium; Rectal Neoplasms; Stomach Neoplasms; Time Factors; Uterine Cervical Neoplasms; Uterine Neoplasms | 1971 |
The risk of bone cancer in man from internally deposited radium.
Topics: Bone Neoplasms; Humans; Neoplasms, Radiation-Induced; Radium | 1968 |
The risk of bone cancer in man from internally deposited radium.
Topics: Bone Neoplasms; Humans; Neoplasms, Radiation-Induced; Radium | 1968 |
Mortality from primary tumours of bone in England and Wales.
Topics: Adolescent; Adult; Age Factors; Aged; Bone Neoplasms; Child; Child, Preschool; Death Certificates; England; Female; Humans; Infant; Infant, Newborn; Male; Middle Aged; Neoplasms, Connective Tissue; Osteitis Deformans; Radium; Sex Factors; Wales; Water Pollution, Radioactive | 1969 |
The relative toxicities of radium 226, plutonium 239 and strontium 90 for bone tumour induction.
Topics: Animals; Bone Neoplasms; Mice; Neoplasms, Experimental; Plutonium; Radiation Injuries, Experimental; Radium; Strontium | 1966 |
DIAGNOSIS OF BONE METASTASIS BY PHOTOSCANNING WITH STRONTIUM 85.
Topics: Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Humans; Male; Neoplasm Metastasis; Neoplasms; Prostatic Neoplasms; Radio; Radioisotopes; Radionuclide Imaging; Strontium; Strontium Isotopes | 1964 |